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Zusammenfassung 
Morbus Dupuytren (DD) ist eine Fibromatose des palmaren Bindegewebes, die zu 
Flexionskontrakturen der Finger führt.  DD hat eine starke genetische Komponente mit einer 
geschätzten Erblichkeit von etwa 80%. Eine frühere kollaborative genom-weite Assoziationsstudie 
(GWAS) identifizierte 9 Suszeptibilitäts-Loci, die zu einem erhöhten Risiko für DD beitragen. Allerdings 
können diese Loci zusammen nur einen Bruchteil der Erblichkeit erklären. Die spezifischen Gene und 
funktionellen Varianten für DD blieben hier unklar. 
Ziel der vorliegenden Forschungsarbeit ist es daher, die zugrunde liegende genetische Architektur von 
DD auf verschiedenen Ebenen systematisch zu untersuchen: i) Identifizierung von funktionellen 
Varianten, die zu einem starken GWAS-Assoziationssignal an einem DD-Risiko-Locus führen, ii) 
Priorisierung von Genen mit seltenen Varianten, die mit dem DD-Phänotyp funktionell in Verbindung 
gebracht werden können, und iii) Charakterisierung der transkriptionellen Deregulation in DD. 
Ein Intervall auf Chromosom 7, am 7p14.1, in dem sich der Einzelnukleotid-Polymorphismus (SNP) 
rs16879765 (G>A) mit der stärksten signifikanten Assoziation mit DD in der genannten GWAS 
befindet, wurde als DD-Suszeptibilitäts-Locus identifiziert. Zuerst haben wir daher eine gezielte 
Anreicherungsstrategie mit anschließender NGS sequenzierung mittels (targeted NGS) verfolgt, um 
eine Region von 500 kb an dem Locus auf 7p14.1 zu untersuchen. Eine seltene aminosäure-ändernde 
Variante, rs149095633 (p.P121L, auf Haplotypen durch das rs16879765*A Risiko-Allel markiert), und 
ein häufiger eQTL-Kandidat, rs2044831 (in mäßigem Kopplungsungleichgewicht (LD) mit 
rs16879765), wurden in EPDR1 identifiziert, einem funktionellen Kandidatengen, das am kontraktilen 
Phänotyp der DD-Primärzellen beteiligt ist. 
Zweitens führten wir eine Pilotstudie zur Exomsequenzierung (WES) bei 50 DD-Patienten mit 
mutmaßlich ausgeprägter genetischer Prädisposition durch und priorisierten Kandidatengene mit 
seltenen Varianten. 3919 seltene kodierende Varianten wurden als nachteilig vorhergesagt. 1774 
Gene mit mehr als 2 Varianten wurden mit „Human Phenotype Ontology“ und „Gene Intolerance 
Score EvolTol“ nach geeigneten Phänotyp-Kategorien und palmarer Expression gefiltert. Als Ergebnis 
wurden 12 Gene als DD-Kandidatengene mit potenziell pathogenen seltenen Varianten priorisiert. 
Insbesondere wurden 6 davon als funktionell wichtige Gene für die DD-Entwicklung eingestuft. 
Drittens führten wir eine umfassende Transkriptomstudie durch RNA-Sequenzierung in 50 DD-
/Kontroll-Biopsieproben durch. Unter Verwendung von Genexpressionsprofilen wurde durch eine 
Perturbationsanalyse der Hippo-Signalweg als ein Schlüsselmechanotransduktionsweg 
vorgeschlagen, der die profibrotische Mikroumgebung in DD vorbereitet. Der TGFβ-Signalweg und 
ECM-Rezeptor-Wechselwirkungen wurden als essenziell für die Gewebefibrose vorhergesagt. 
Darüber hinaus wurden durch die Analyse von alternativem Splicing (AS) charakteristische 
Isoformprofile und Isoformverwendungen in DD-Gewebe gefunden. Diese Isoformen könnten an 
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einem Mechanismus beteiligt sein, mit dem sich Zellen in betroffenem Gewebe an Fibrose anpassen 
und die Fibroseprogression weiter fördern. 
Zusammengefasst charakterisiert diese Studie erstmals einen GWAS-Risikolocus für DD und bietet 
einen Ansatz für die Identifizierung funktioneller Varianten für DD im Post-GWAS-Zeitalter. Die 
explorative Priorisierung von DD-assoziierten Kandidatengenen unterstützt die Annahme, dass 
seltene Varianten einen Beitrag zur Entwicklung der Krankheit leisten, und benennt Kandidatengene 
für Folgestudien. Zudem liefert diese Studie neue Anhaltspunkte für einen Zusammenhang zwischen 
wichtigen physiologischen Pfaden und der transkriptionellen Regulation von DD und bietet einen 
ersten Einblick in spezifisches AS in betroffenem Gewebe und die damit verbundenen AS-
Regulationsmechanismen. Unsere Studie stellt einen ersten Schritt zur Integration versoliedener 
genomischer Ansätze mit dem Ziel dar, um die mechanistischen Verbindungen zwischen der 
genetischer Prädisposition und der Ausprägung von DD aufzuklären. 
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Abstract 
Dupuytren's Disease (DD) is a fibromatosis in the palmar connective tissue that leads to flexion 
contractures of fingers. DD has a strong genetic component with an estimated heritability of about 
80%. A previous collaborative genome-wide association study (GWAS) has mapped 9 susceptibility 
loci that were shown to contribute to the increased risk of DD. However, these loci together can only 
explain a small fraction of heritability. Moreover, the respective genes and functional variants 
underlying DD remained unclear. 
Therefore, the present study aims to systematically investigate the genetic architecture of DD at 
different levels by: i) identifying functional variants contributing to a strong GWAS association signal at 
a DD risk locus, ii) prioritizing DD phenotype-related genes with rare variant burdens, and iii) 
characterizing the transcriptional deregulation in DD.  
An intervall on chromosome 7, 7p14.1, tagged by rs16879765 (G>A), which was most significantly 
associated with DD in the previous GWAS, has been identified as a DD susceptibility locus. Therefore, 
we first used a target-enrichment strategy coupled with next generation sequencing (targeted NGS) to 
assess a 500kb region at 7p14.1. A rare non-synonymous variant, rs149095633 (p.P121L, on 
haplotypes tagged by the rs16879765*A risk allele), and a common eQTL candidate, rs2044831 (in 
moderate linkage disequilibrium with rs16879765), were identified in EPDR1, a functional candidate 
gene contributing to the contractile phenotype of DD primary cells.  
Second, we performed a pilot whole exome sequencing (WES) study in 50 DD patients with suspected 
high genetic predisposition and prioritized candidate genes with rare variant burden. 3919 rare coding 
variants were predicted to be deleterious. 1774 genes with gene burden greater than 2 were filtered 
for suitable phenotype classes and palmar expression according to Human Phenotype Ontology and 
the gene intolerance score EvolTol. As a result, 12 genes were prioritized as DD candidate genes with 
potentially pathogenic rare variants. In particular, 6 of these genes were suggested as functionally 
important for DD development.  
Third, we carried out an elaborate transcriptome study in 50 DD/control biopsy samples by RNAseq. 
By pathway perturbation analysis using gene expression profiles, the Hippo signaling pathway was 
suggested as a key mechanotransdution pathway to prepare the profibrotic microenvironment in DD. 
The TGFβ pathway and ECM-receptor interactions were predicted as pathways essential for tissue 
fibrosis. Moreover, by alternative splicing (AS) analysis, DD tissue was suggested to harbor distinctive 
isoform profiles and isoform usage, which might provide a mechanism for cells in disease tissue to 
adapt to fibrosis and further promote fibrosis progression. 
In summary, this study characterized for the first time a GWAS risk locus for DD and provided an 
approach for identifying functional variants for DD in the post-GWAS era. The exploratory prioritization 
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of DD-related candidate genes supported the assumption that rare variants can contribute to the 
development of the disease and nominated candidate genes for follow-up studies. Furthermore, this 
study proposed key physiological pathways involved in transcriptional regulation of DD and gave a first 
insight into disease tissue-specific AS and possible AS regulation mechanisms. Overall, our study 
represents a first step in integrating various genomic approaches to elucidate the mechanistic links 
between the genetic predisposition and the development of DD.  
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Chapter 1 Introduction  
1.1 Dupuytren's disease (DD) — a complex fibrosis disorder 
Most common diseases, such as cancer, diabetes, Alzheimer disease and epilepsy, have a complex 
etiology. Unlike rare Mendelian disorders characterized by single-gene mutations, complex disorders 
are caused by a combination of genetic and environmental factors (e.g. aging, nutrition and life style). 
Aging is a major risk factor for many chronic diseases, yet, the basic mechanisms that drive aging 
remained largely unknown due to several reasons such as the complexity of the aging process at 
molecular, cellular and organ level and the considerable heterogeneity among individuals1. 
Dupuytren’s Disease (DD) is a common connective tissue fibrosis disorder with a prevalence of 2.5% 
in Germany2. The worldwide prevalence of DD is related to geographic location with highest 
prevalence in Scandinavia, UK, Ireland, Australia and North America 3-5.  Other factors including 
trauma and exposure to vibrating machinery are also suggested to increase the danger of developing 
DD6. The manifestation rate of DD is positively correlated with increased age peaking in the sixth and 
seventh decade of life in men and women, respectively7. However, unlike many multifocal aging-
associated diseases, DD is specially localized in the hands.  
DD patients commonly first display benign nodules in the palms (Figure 1-1). These nodules are 
characterized by a high amount of proliferating fibroblasts and their differentiation towards 
myofibroblasts followed by progressive formation of cords consisting mostly of extracellular matrix 
(ECM) proteins8. The maturation of cords is accompanied by fibrosis and ultimately leads to digital 
contractures resulting in hand deformity and impaired hand function in daily life6. The treatment of DD 
consists largely of surgical removal of the contracted tissue, which is unfortunately accompanied with 
a high risk of neurovascular injury and DD recurrence (8% — 66%)9,10. However, the availability of 
affected tissues as well as the unifocal feature of DD enables us to use this disease as a unique 
model for studying the molecular mechanisms of aging-related disorders in connective tissue.  
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Figure 1-1 The clinical presentation of DD 
(A) Benign nodules commonly first displayed in the palms of DD patients (Grade 1). The nodules are 
characterized by a high amount of proliferating fibroblasts and their differentiation towards 
myofibroblasts, followed by the progressive formation of cords consisting mostly of extracellular matrix 
proteins (Grade 2). The maturation of cords ultimately leads to digital contractures resulting in the hand 
deformity (Grade 3). The figure was adapted from http://www.chennaiplasticsurgery.in/ 
Dupuytren's%20contracture.html. 
(B) Treatment of DD consists largely of surgical removal of the contracted tissue, named as DD tissue. 
The figure was adapted from Shil et.al. 6 
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1.1.1 Major cell types in DD — activated fibroblasts and myofibroblasts 
In normal connective tissues, the resident fibroblasts, which are embedded in loosely arranged ECM, 
maintain tissue homeostasis not only by synthesizing ECM proteins including interstitial collagens, 
proteoglycans and adhesive non-collagenous proteins, but also by exerting mild contractile force on 
this ECM11. Very low levels of growth factors, cytokines and blood plasma proteins percolate through 
this microenvironment, which maintains fibroblasts in a 'quiescent' state11.  
During normal tissue repair such as wound healing, fibroblasts become activated and a set of cellular 
and extracellular events take place to repair the damage including four sequential yet overlapping 
phases: inflammation, proliferation, contraction and remodeling11. The cellular contraction accounts for 
a key phase in normal wound healing as it enables wound closure, however, if contraction is 
abnormally persistent, it can lead to tissue fibrosis6, for example, DD. 
The digital contracture phenotype of DD is mainly caused by an increased amount of activated 
fibroblasts and their differentiated myofibroblasts in the palmar fascia. The myofibroblasts, which 
display molecular and cellular phenotypes between fibroblasts and smooth muscle cells, are 
characterized by a flattened spindle shape, excessive ECM deposition and expression of α-smooth 
muscle actin (α-SMA, an early differentiation marker of vascular smooth muscle cells)12,13. The 
expression of α-SMA is a molecular hallmark to distinguish myofibroblasts from 'quiescent' fibroblasts. 
Upon tissue injury, the resident 'quiescent' fibroblasts are activated by both cytokine signaling and 
mechanical change of microenvironment and differentiate into a myofibroblast phenotype11.  
Then, the differentiated myofibroblasts incorporate α-SMA in stress fibers and develop adhesion 
complexes with ECM termed 'fibronexus' in vivo or 'super mature focal adhesions' in vitro. The 
adhesion complexes bridge the myofibroblasts' internal microfilaments with ECM and thus enable 
these cells to generate contractile forces surrounding the ECM. In pathological situations, the 
contractile activity in myofibroblasts is abnormally maintained over time and enhanced by the 
deposition of excessive ECM in their surrounding niche14,15. 
The origins of activated fibroblasts and myofibroblasts in fibrotic tissues still remain unclear. Recent 
studies on some fibrosis disorders and cancer have suggested a heterogeneous origin of activated 
fibroblasts and myofibroblasts in tissue fibrosis. Proposed major contributors include bone marrow-
derived fibroblasts, adipocytes, epithelial cells and endothelial cells (Figure 1-2)11,16. However, the 
molecular mechanisms by which this differentiation occurs in DD remain not well understood. 
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Figure 1-2 Possible origins of myofibroblasts 
In some fibrosis disorders and cancer, myofibroblasts are suggested to originate directly or indirectly 
from various cells such as resident fibroblasts, adipocytes, bone marrow derived mesenchymal stem 
cells, epithelial cells (through epithelial mesenchymal transition: EMT) and endothelial cells (through 
endothelial mesenchymal transition: endMT) etc. The figure was adapted from Shiga et al.16 
 
1.1.2 DD — associated with low BMI and type 2 diabetes 
DD appears to be associated with other complex traits17. In the Reykjavik Study including 1297 men, 
elevated fasting blood glucose low body mass index (BMI, a marker for adiposity), were significantly 
correlated with the presence of DD18. The association between DD and low adiposity suggests 
common genes or pathways involved in diseases susceptibility.  
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1.2 The genetic background of DD 
Compelling evidence, including frequent familial clustering and high Caucasian prevalence compared 
to other ethnic groups5,18, consistently suggests genetic factors to contribute to the onset of DD.  
In order to identify genetic risk loci associated with Dupuytren´s disease, a collaborative genome-wide 
association study (GWAS) including 2,325 DD cases and 11,562 controls was conducted by groups in 
Groningen (the Netherlands), Oxford (UK) and our group (Germany) to identify associations between 
the disease and common genetic markers. As a result, 11 single nucleotide polymorphisms (SNPs) in 
9 different loci were found to be significantly associated (p<5.0x10–8) with DD, implicating a genetic 
susceptibility to DD.  
The top GWAS SNP, ranked by the lowest p-value was found in the intronic region of EPDR1/SFRP4 
(rs16879765, p=5.6×10−39; odds ratio, 1.98). Five further loci were found to harbor genes encoding 
proteins of the WNT/β-catenin signaling pathway19, which are WNT4 (rs7524102, p=2.8×10−9; odds 
ratio, 1.28), WNT2 (rs4730775, p=3.0×10−8; odds ratio, 0.83), RSPO2 (rs611744, p=7.9×10−15; odds 
ratio, 0.75), WNT7B (rs6519955, p=3.2×10−33; odds ratio, 1.54) and SULF1 (rs2912522, p=2.0×10−13; 
odds ratio, 0.72), suggesting that variants in genes involved in the WNT/β-catenin signaling pathway 
may cause a predisposition to DD.  
In total, the 9 risk loci identified in this GWAS could explain about 1% of the heritability of DD.  
Moreover, all the 9 loci were further validated in a study20 combining three imputed GWAS data sets 
including 1580 cases and 4480 controls from the Netherlands (the previous Groningen study)19, 
Switzerland and Germany. Six of these loci reached genome-wide significance (p<5x10-8). In sum, 
these GWAS results provided the first solid piece of evidence, which greatly improved our 
understanding of the genetic basis of DD.  
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1.3 The unclear genetic architecture of DD 
1.3.1 The missing genetic causes of GWAS loci  
A more recent association study, involving 30,330 Danish monozygotic and heterozygotic twins, was 
conducted to assess the relative contribution of genes and environment in the etiology of DD21. A high 
heritability (80%) was estimated for DD occurrence suggesting a major role of genetic factors in the 
development of DD21. Thus, a large portion of the genetic heritability was not explained by 
previous GWAS leading to the arising question of how the 'missing heritability' of DD can be 
explained.   
One explanation refers back to the initial basis of conducting GWAS, the 'common disease–common 
variant' hypothesis, which states that most of the genetic risks for common diseases are due to loci 
where common functional variants (minor allele frequency [MAF] > 5%) exist at each locus22. 
Therefore, GWAS applies an indirect association approach to identify tag SNPs associated with the 
disease phenotype. However, the GWAS tag SNPs are not necessarily biologically meaningful, but 
strongly correlated with the underlying functional variants22. This correlation is known as linkage 
disequilibrium (LD), the non-random combination between alleles at linked loci along a chromosome, 
which in part, reflects their proximity and the correspondingly low probability of recombination breaking 
the haplotype on which they are found.23 
Recently, the fast development of next generation sequencing (NGS) has created the opportunity to 
directly map the variants. In particular, by target enrichment and NGS (Targeted NGS) of a GWAS-
associated locus, the variability of the entire locus can be exhaustively identified, including coding and 
noncoding regions comprising all common and rare variants. Rare genetic variants affecting protein 
coding were recently identified to have a strong effect on the susceptibility of complex diseases, for 
example, Alzheimer's disease24. In addition, common variants associated with gene expression are 
increasingly shown to harbor regulatory roles by manifesting themselves as cause of gene expression 
differences25. Mapping of expression quantitative trait loci (eQTL) is one way to identify regulatory 
variants affecting gene expression. Several comprehensive projects including Genotype-Tissue 
Expression (GTEx), have established as a resource databases to search for eQTL in human normal 
tissues25,26. Combining eQTL data with disease associated genetic variants provides an opportunity to 
identify common regulatory variants influencing gene expression at GWAS loci.  
Given that consistent evidence of several susceptibility loci linked to DD, fine mapping of GWAS-
associated loci should be performed to identify functional rare and common variations represented by 
GWAS association signals. 
1.3.2 The contribution of rare variants and candidate genes to DD 
Over the past several years, the 'common disease–common variant' hypothesis was increasingly 
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challenged by the 'common disease–rare variant' hypothesis, as a growing body of evidence suggests 
that rare variants with a MAF of less than 5% also play an important role in complex trait etiology27. 
Currently, the widely accepted model for the genetic architecture of common diseases is the 'broad 
sense heritability' model, which refers to not only genetic components (which includes a large number 
of rare variants with a large-effect size and common variants with a small-effect size), but also the 
interactions between genetic components and environmental factors22.  
For DD, common variants tagging genetic risk loci have been captured by GWAS, however, all of 
them are in the non-coding regions of the genome and many of them are in intergenic regions. This 
makes it hard to address their functional consequences and identify candidate genes contributing to 
the DD phenotype. On the hand, the impact of rare variants on DD phenotype remains unanswered 
since the low-frequency variants cannot be completely represented by GWAS using genotyping 
arrays.  
In the past few years, whole exome sequencing (WES) of all protein-coding regions has been 
considered a powerful tool to discover genes underlying unsolved Mendelian disorders28. More 
recently, WES was also used to prioritize candidate genes29,30 and evaluate the contribution of rare 
variants to genetic heritability in complex diseases31,32. To date, no published WES studies on rare 
genetic variants have been reported in DD.  
1.3.3 Transcriptome characterization of DD   
Identifying genes carrying genetic variants is only one part of genetic studies. The ultimate goal is to 
understand the functional relevance of these candidates and the underlying disease biology. Whole 
transcriptome analysis of disease tissues/cells can provide the foundation for the understanding of the 
contribution of genetic variants, gene function and pathogenic mechanisms involved in diseases. 
1.3.3.1 Findings and problems in previous gene expression profiling studies in DD  
Global gene expression in DD has been studied in DD tissue biopsies or patient-derived cells using 
microarrays in several groups8,33. These studies have provided important insights for deregulated 
genes and pathways involved in DD.  
An elevated level of β-catenin was detected in the DD tissues compared to patient-matched fat 
controls as well as in primary DD cells derived from DD tissues on collagen lattice34. No genetic 
variants were identified in CTNNB1, which encodes β-catenin, in DD patients by Sanger sequencing. 
Therefore, the altered expression of β-catenin may be explained by alterations of WNT/β-catenin 
pathway components or other pathway components, which modulate β-catenin stability34, for example, 
by transforming growth factor-beta (TGFβ) pathway components35-37. In accordance with virtually all 
other fibrosis disorders, the TGFβ pathway is considered as a master regulator in DD by regulating 
fibroblasts proliferation and their differentiation into myofibroblasts12,38. Additionally, the increased β-
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catenin expression observed in DD cells collagen lattice cultures suggests a potential role of ECM in 
modulating β-catenin levels in DD34.  
A number of microarray studies have been attempted to explore the abnormalities of ECM in DD. The 
high expression of various ECM components, such as COL1A133,39, COL3A133,39, COL4A239, 
COL5A139 and TNC33,39, was observed in DD nodules. Increased expression of MMP14 was also 
detected in DD nodules and associated with recurrence of nodules following surgical intervention in 
DD cases40. These studies provided important insights in the abnormal characteristics of the ECM in 
DD relevant tissues. However, the exact cause of the differential expression and the function of these 
components are still not clear, which may be due to several reasons.  
First, it is difficult to define the function of a candidate gene using pure expression profiling 
information, which, by its nature, only captures the mRNA activity in tissues at the disease state 
without knowing genetic or mechanistic dysfunction. Including genetic information, for example WES 
data of patients, should facilitate the prioritization of the functional genes involved in transcriptional 
regulation.  
Second, the controls used in previous expression profiling studies were insufficient. In some studies, 
the gene expression profiling for DD tissues (DDtis) was compared with internal controls, the 
unaffected palmar fat (DDfat) tissues from the same patients. While in other studies, the external 
controls  — palmar fat tissues from patients undergoing open surgical carpal tunnel release (CTtis) 
were used as healthy tissue controls, since the truly healthy palmar tissues from healthy people are 
not available due to practical issues. Very rarely, both internal and external tissue controls were 
included in expression analysis41. 
Third, the absence of appropriate animal models, owing to the unique anatomical and functional 
features of hands, makes it difficult to design reliable in vivo functional studies. So far, the culture of 
primary cells derived from DD tissues (DDcell) served as the in vitro experimental model for DD to 
study gene function. However, one of the significant differences of cultured cells compared to in vivo 
tissues is the lack of ECM structural support and growth factor secretion.  
In addition, although microarrays have enabled rapid and cost-effective analyses of gene expression 
profiling in DD tissues, there are still several weaknesses of this technique, such as the limited 
detection of low-abundance transcripts and identification of novel transcripts.  
In contrast, the recent development of RNA-seq offers a great power to analyze gene expression at a 
high resolution and investigate different layers of transcriptome complexity42. RNA-seq analyzes the 
complementary DNA (cDNA) by means of NGS and maps sequence reads onto the reference 
genome. The massive capacity of RNA-seq allows not only the measurement of low abundance 
transcripts, but also the identification of novel transcripts and alternative splicing patterns associated 
with traits, which may be crucial in disease pathogenesis. 
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1.3.3.2 The unknown role of alternative splicing (AS) in DD 
In humans, a gene has approximately 9 exons and 8 introns on average43. Genes need to be 
transcribed over their full length (including both introns and exons) to generate primary mRNAs or 
precursor mRNAs (pre-mRNAs). The introns are then removed from the pre-mRNAs and exons are 
joined together to form the functional mRNA. This process is catalyzed around splice sites at the ends 
of each intron by spliceosome, a highly dynamic ribonucleoprotein (RNP) complex comprised of five 
small nuclear ribonucleoproteins (U1, U2, U4/U6 and U5) and numerous other proteins44. From a 
given pre-mRNA to mature mRNAs, some constitutive exons are spliced into every mRNA produced, 
whereas many exons are alternatively spliced into various mRNA isoforms leading to the synthesis of 
different protein isoforms with diverse functions45. This process is defined as alternative splicing (AS). 
There are six common types of AS events (Figure 1-3), which include exon skipping/inclusion (ESI), 
intron skipping/inclusion (ISI), alterative 5' splice sites (A5), alternative 3' splice sites (A3), multiple 
exon skipping (MESI) and mutually exclusive exons (MEE) (Figure 1-3)46. ESI is known as the most 
common splicing phenomenon in eukaryotes, describing that an exon is spliced in or out of the 
transcript thereby leading to extended or shortened mRNA isoforms47. A5 and A3 events occur when 
two or more splice sites are recognized at one end of an exon/intron. They account for 7.9% and 
18.4% and of all AS events in higher eukaryotes, respectively47. The ISI event is defined by the 
retention of an intron in the mature mRNA transcript, accounting for less than 5% of known events in 
vertebrates and invertebrates47. MESI or MEE are complex AS events, which are subject to specific 
regulation48. 
In general, AS is tightly regulated in a tissue- or cell-specific manner. The splicing regulatory 
sequences and RNA-binding splicing factors, which recognize and bind to these sites, compose a 
common mechanism for setting up and maintaining AS patterns45. Tissue-specific splicing factors may 
activate or inhibit the use of splice sites or act in both ways depending on the sequence and position 
of the target site in the pre-mRNA.  
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Figure 1-3 A schematic representation of common alternative splicing events 
Six major splicing events were represented, which are exon skipping /inclusion (ESI), intron 
skipping/inclusion (ISI), alterative 5' splice sites (A5), alternative 3' splice sites (A3), multiple exon 
skipping (MESI) and mutually exclusive exons (MEE). The figure is modified from Vitting-Seerup et al.46 
 
 
Unraveling AS of genes at the molecular level is important for understanding not only gene 
expression, but also disease causation as aberrant pre-mRNA splicing is the basis of many complex 
diseases. Here are three examples: first, the imbalanced ratio of 4R/3R tau isoform ratio, due to 
inclusion/exclusion of exon 10, is linked to tau-related neurodegeneration, for example Alzheimer 
disease. Second, the lack of SMN1 isoform (survival of motor neuron), which is required for assembly 
of macromolecular splicing factors, causes spinal muscular atrophy. Additionally, the dysregulation of 
the splicing process is common in cancer. This may include deregulated genome-wide splicing events, 
differentially expressed splicing factor genes, and aberrantly spliced cancer-critical genes. All this may 
contribute to tumorigenesis and tumor severity. One well-documented example is the association 
between aberrantly spliced CD44 isoforms and metastasis49.  
So far, studies on the presence and regulation of AS in DD are completely lacking. Therefore, 
investigations of AS and their contribution to the DD phenotype is in great need and will broaden our 
understanding of the transcriptional misregulation in DD. 
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1.4 The aim of this project 
DD represents an ideal, however not well studied, disease model to study aging-related diseases with 
high genetic susceptibility. Investigations to unravel the genetic architecture and molecular etiology of 
DD may offer an opportunity to develop biomarkers for prognosis and the selection of non-operative 
treatment strategies. To date, the genetic architecture of DD is mostly unknown due to the complex 
interactions between genes and environmental factors. So far a few risk loci explaining only about 1% 
of the genetic heritability have been identified by previous GWAS studies, however, many more 
genetic components are expected to exist.  
Therefore, this thesis aimed to  
1) identify functional variants at a DD risk locus using targeted NGS 
2) prioritize DD phenotype-related genes carrying rare variants using WES 
3) characterize the transcriptional deregulation in DD tissues/cells using RNA-seq.  
 
   
 18 
Chapter 2 Method  
2.1 Study design, subjects and ethical approval 
The study design of this project is shown in Figure 2-1. The samples from participants were collected 
after written informed consent according to the protocols approved by the participating institutions. All 
participants are of European origin. Patients with DD were recruited. DNA was extracted from 
peripheral blood samples for targeted NGS and WES. RNA was isolated from disease relevant 
tissues/cells of patients undergoing a standard fasciectomy. Control palmar connective tissue/cell 
samples were obtained from patients undergoing carpal tunnel (CT) release. The Ethics Commission 
of the Faculty of Medicine of the University of Cologne fully approved the study. 
            
              Figure 2-1 The study design of the project 
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2.2 Targeted NGS and data analysis  
2.2.1 Target NGS and variant calling  
Guided by LD structure (Figure 3-1), we selected a 500kb region (chr7: 37.77-38.27kb) containing the 
leading SNP rs16879765 on 7p14.1 for targeted sequencing. DNA was isolated from peripheral blood 
of 96 DD patients. The DD-associated locus was enriched using the SureSelect XT2 kit (Agilent). 
Libraries were prepared and labeled with barcodes for 100bp paired-end sequencing on the HiSeq 
2000 device (Illumina) at the Cologne Center for Genomics (CCG). Sequence reads in FastQ format 
were mapped to the hg19/GRC37 reference genome using Varbank pipeline 2.16 
(https://varbank.ccg.uni-koeln.de). Variant calling was performed using GATK v1.650 (in Varbank 2.16 
pipeline) and 91.5% bases were called with calling accuracy more than 99.99% (Phred quality score 
30). The mean target coverage was 77x. At 10x/30x coverage, 96%/91% of the region was covered. 
Annotation of variants was performed using Varbank 2.16 and Ensembl VEP 2.751. 
2.2.2 Validation and replication using Sanger sequencing  
Sanger sequencing was performed on the fifth exon of EPDR1 gene. For standard PCR reactions, A 
10 ul reaction was pipetted with 10 ng of genomic DNA, 0.25 ul BigDye terminator v3.1 (Applied 
Biosystems), 1.125 µM BigDye sequencing buffer and 0.25 µM primers (Eurofins). Cycling conditions 
were as follows: 96 °C for 10 seconds, 55 °C for 5s, 60 °C for 4 minutes, and the cycle was repeated 
32 times. The quality of the PCR product was examined on an electrophoresis gel and only high 
quality PCR products were further cleaned. For a 10 µl PCR product cleanup reaction, 3 U 
Exonuclease I (Neo Lab), 0.9 U SAP (Shrimps Phosphatase Alkali, Promega), 2-10 ng PCR product 
and H2O was mixed and incubated at 37˚C for 20 minutes and then at 85˚C for 15 minutes.  Samples 
were stored at 4 ˚C until needed.  
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2.2.3 Pyrosequencing 
Template DNA (6ng genomic DNA or external cDNA products) was amplified using HotStarTaq Plus 
DNA Polymerase kit (Qiagen) using stand reaction (2 U HotStarTaq Plus DNA polymerase, 1x PCR 
buffer, 200 µM of each dNTP and 0.1 µM of each primer) and amplification conditions (95 °C for 5 
minutes, 30 cycle of 3 step cycling including 94 °C for 30 seconds, 60 °C for 30 seconds and 72 °C for 
1 minute as well as final extension at 72 °C for 10 minutes). Reverse PCR primers were biotinylated 
for subsequent pyrosequencing analysis. Pyrosequencing reactions were carried on PSQ HS96A 
instrument and pyrosequencing SNP analysis software (PyroMarkTMQ96MD, Qiagen). 
Pyrosequencing signals for alternative alleles were normalized to signals for known reference alleles. 
Significant allele specific expression was normalized from experimental noise using T-test  (p<0.05).  
2.2.4 Protein model  
Gremlin global statistical model method52 was used to generate a multiple sequence alignment and 
construct the protein model for EPDR1. The EPDR1 protein sequence was searched against UniProt 
and the significant hits were added to an alignment, which was further searched against Uniprot. This 
procedure was repeated 4-8 times and a diverse alignment for the entire family of EPDR1 -like protein 
was identified. This alignment was then compared to a database of alignments (protein data bank, 
PDB) using HHsearh Jackhmmer (EBI). The alignment-to-alignment search eventually revealed the 
best hit to 3bmz in PDB database with 94% confidence that 3bmz shared the same folding with 
EPDR1. After threading and refining with co-evolution data and Rosetta v3.2, the best predicted model 
is shown in Figure 3-3A.  
2.2.5 Transcription factor binding sites 
We performed the prediction of transcription factor (TF) binding sites for rs149095633 using two 
bioinformatics tools: the Genomatix MatInspector53 and TRANSFAC databases54. Genomatix 
MatInspector is a software tool that utilizes a large library of matrix descriptions for transcription factor 
binding sites (also named as motif) to locate matches in DNA sequences54. It uses two scores 
including the matrix similarity score and core similarity score to measure the quality of a match 
between the sequences and the consensus TF binding site matrix, which ranges from 0 to 1 with 1 
denoting an exact match53. The core of each matrix is defined as the first five most conserved 
consecutive positions of a matrix53. Using TRANSFAC database, the consensus TF binding site matrix 
and the core of each matrix can be visualized in motif logos (for example, in Figure 3-4B), which 
scales each nucleotide by the total bits of information multiplied by the relative occurrence of the 
nucleotide at the position55.  
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2.3 Whole exome sequencing (WES) and data analysis 
2.3.1 Exome sequencing and variant calling 
Blood DNA was isolated from 40 DD patients. Library construction and exome capture were performed 
with the SeqCap EZ Human Exome Library v2.0 (NimbleGen). The prepared library was sequenced 
on Illumina HiSeq 2000 using paired-end 100bp sequencing at CCG. Variants were called using using 
GATK HaplotypeCaller50  under standard hard filtering parameter and variant quality score 
recalibration according to GATK Best Practices recommendations56,57. This allowed variant calling 
simultaneously using local de novo assembly and a Bayesian statistical model.  
In total, 3.48 billion sequencing reads were aligned to the human genome (hg19/GRC37), with a 
99.5% mean coverage across the exome region in 40 samples. In each sample, at least 20x/30x 
coverage of 95%/90% exome region of was achieved. A total of 4,214,948 loci in VCF file passed QC 
threshold, representing 3,933,980 SNPs and 301,509 indels/substitutions. Only high-confidence 
variants (99,323 variants with "High Qual") were further annotated by Annovar tool.  
 2.3.2 Annotation of variants by Annovar 
ANNOVAR (2016Feb01)58 was used to annotate high-confidence variants (99,323 High Qual variants) 
called from GATK. Variants were annotated and filtered for function priority (missense, nonsense and 
splice variants), conservation, rare variants (MAF ≤ 1% in large population database) and functional 
consequences (SIFT<0.05 applied, which predicts an amino acid substitution affects protein function 
based on the degree of conservation of the amino acid residues59) using annotate_variation.pl 
function. In total, 3919 variants in 3088 genes were considered as fictional rare variant candidates 
(Figure 3-6A). Variants were validated by read alignments visualization using Varbank 2.16 'Browse 
Reads' and IGV60.  
2.3.3 Phenotype-based gene prioritization 
The Phenolyzer (Phenotype Based Gene Analyzer)29 tool was used to prioritize genes based on DD 
related phenotypes, which includes 'flexion contracture of finger', 'connective tissue' and 'fibrosis'. In 
total, the three phenotypes and 3088 genes carrying rare variants (from Annovar) were used as input 
in the Phenolyzer. As a result, 88 genes were identified as highly related to three DD phenotypes 
(phenolyzer score ≥ 1). An overlapping list of 30 genes between 88 DD phenotype-related genes and 
1774 genes with gene burden greater than two were prioritized (Figure 3-7A). 
2.3.4 GESA of pathogenicity 
The WGPA-GSEA tool61,62 calculated if the genic intolerance scores EvolTol63 (genome-wide score in 
the palmar part of the hand) of a list of genes occupy higher positions in the ranked gene list than it 
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would be expected by chance. Gene set enrichment scores and significance level of the enrichment 
(FDR adjusted q-value) suggests the list of 30 genes from Figure 3-7A was significantly enriched for 
intolerant genes in the palm (Figure 3-7B), which included 12 genes predicted as the top 25% genes 
that are intolerant to mutations in  the palm tissue (Figure 3-7C, Table 3-5). 
2.3.5 GO and pathway analysis using Enrichr 
The gene ontology (GO)64 covers three domains: biological processes, cellular components and 
molecular functions. The Enrichr65 tool was used to detect GO features of 12 candidate genes 
(Table 3-5) beyond that which would be expected by chance (Fisher’s exact test, Bonferroni 
adjusted p-value ≤ 0.05 is applied) (Table 3-6). Enrichr pathway analysis was used to map genes to 
KEGG pathways66. The p-value denotes the significance of the pathway correlation (Bonferroni 
adjusted p-value ≤ 0.05 was applied) (Table 3-7).  
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2.4 RNA-seq and whole transcriptome analysis 
In this project, we propose that an appropriate transcriptome study design should involve not only the 
disease tissue, but also internal and external controls to interpret the origins of the observed changes 
in gene expression in disease tissues.  
By comparing DDtis (palmar nodule biopsy from DD patients) to external tissue controls CTtis (palmar 
fat from carpal tunnel patients, which are considered as CT healthy controls without DD), the general 
DD-related changes in gene expression could be unraveled, though, the changes represent a mix of 
differences including the difference in genetic background between DD patients and CT controls and 
the difference in tissue types between DDtis  (the nodule or cord tissues) and CTtis (mainly fat tissue). 
However, by comparing gene expression profiling between two fat controls, including internal control 
DDfat (perinodular fat from DD patients) and external fat control CTtis, the contribution of genetic 
components might be observed since both tissues are the same tissue type. Moreover, by comparing 
DDtis to DDfat  — the fat tissue adjacent to DDtis, disease specific features could be identified.  
In addition, by including DDcell (DDtis derived in vitro cells) and control CTcell (CTtis derived in vitro 
cells), an evaluation of the true in vivo relevance of the in vitro cell model could be conducted by 
comparing the gene expression profiling of DDtis/CTtis and DDcell/CTcell. 
A flowchart illustrating the different analyses of RNA-seq data performed in this project is provided in 
Figure 2-2. 
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Figure 2-2 A schematic representation of the RNA-seq pipeline   
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2.4.1 RNA isolation  
Using InviTrap Spin Universal RNA kit (Stratec Biomedical), total mRNA was extracted from DDtis 
(n=10), DDfat (n=9) and DDcell (n=10) from 11 DD patients as well as from CTtis (n=10) and CTcell 
(n=10) from 11 CT control people (Table 3-8). The RNA concentration was assessed via NanoDrop 
ND-8000 spectrophotometry (Thermo Scientific). The quality of the total RNA was evaluated using 
both agarose gel electrophoresis and Bioanalyzer 2100 (Agilent). 
2.4.2 Library preparation and sequencing 
For mRNA-seq sample preparation, the TruSeq stranded mRNA library prep kit (Illumina) was used. 
First, 1µg of each total RNA sample was used for polyA mRNA selection using streptavidin-coated 
magnetic beads. The polyA selected mRNA was fragmented and amplified for cDNA synthesis using 
reverse transcriptase and random hexamer priming. In addition, the amplified cDNA underwent double 
stranded cDNA conversion, end repair and adaptor ligation. The gel purification (2% agarose gel) was 
used for size selection and cDNA libraries ranging in size from 200–250 bp were generated. Finally, 
the libraries were amplified using PCR (15 cycles) and quantified using Bioanalyzer 2100 (Agilent). 
Each library was run at a concentration of 7pmol using paired-end 75 bp sequencing on a HiSeq 4000 
device (Illumina).  
2.4.3 RNA-seq read mapping, transcript assembly and abundance estimation  
In total, 32 billion reads were sequenced on HiSeq 4000 device. An average of 64 million reads (75bp 
paired-end) per sample were sequenced and aligned to the hg19/GRC37 (Ensembl 75) human 
genome using TopHat 2.1.1 (based on Bowtie)42, which truncated each read of the pair to 25nt and 
aligned each end of the pair separately under mammalian default parameters, leading to an average 
mapping of 92.8% with a standard deviation of 5.3%.  
The aligned reads were then assembled by Cufflinks package (including Cufflinks, Cuffmerge and 
Cuffcompare)42 to reveal novel transcripts and genes as well as low abundance transcripts. The 
relative abundance of each transcript was normalized to Fragments Per Kilobase of exon per Million 
fragments (FPKM)42.  
Cuffdiff program was used for differential analysis of each transcript and gene between two conditions. 
With multiple replicates, Cuffdiff learns how read counts vary for each gene across the replicates and 
uses the variance estimates to calculate the significance of observed changes in expression42. A t-test 
was used on ratio of log transformed FPKM between two condition, which approximately follows a 
normal distribution42. Limma (moderated t-statistic) was used to calculate p-values using empirical 
Bayes estimates for standard error and degrees of freedom42.  
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In each comparison, genes with minimum FPKM values of expression higher than 1 (minFPKM≥1) in 
either condition were first selected. Then, genes with |fold change| ≥ 1.5 (that is |log2 old change| ≥ 
0.6) and FDR adjusted p-value ≤ 0.05 after Benjamini-Hochberg correction for multiple-testing with 
significance level "yes" were considered as significantly DEGs . The gene expression volcano plots 
were derived from iPathwayGuide tool.  
2.4.4 GO overrepresentation and pathway perturbation  
The Cuffdiff results of differential gene expression analysis were uploaded to the iPathwayGuide tool 
(www.advaitabio.com/ipathwayguide.html)67,68. The DEGs were annotated for overrepresented GO 
features64 and perturbed KEGG pathways66 using iPathwayGuide. 
For the large DEG sets, to reduce the false positive rate caused by GO term 'inheritance problem'  — 
the higher level (more general) GO terms inherit annotations from the lower level (more specific) 
descendant terms, a minimum elim adjusted p value 0.05 was used a cuts-off to screen the GO term 
enrichment69. The elim (elimination gene) method first investigates the GO terms from bottom to — 
top, the more specific to more general and then removes the genes mapped to significant GO terms 
from higher level (the more general level)69.  The pathway perturbation was analyzed on DEG sets.  
The iPathwayGuide employs a third generation pathway topology (PT)-based pathway perturbation 
analysis68 by evaluating both pathway over-representation and accumulation. For over-representation 
analysis, the number of DEGs involved in a pathway was compared between two comparisons. For 
pathway accumulation analysis, the significance of a particular DEG to a pathway was considered in 
determining the overall impact on the pathway by examining all annotated functions/interactions of the 
gene in KEGG pathway databases66.  
The results are shown in scatter plots. For example, in Figure 3-11A, each round circle represents a 
pathway. The x-axis represents the significance of pathway overrepresentation (–log10OVA p-value). 
The y-axis represents the significance of pathway accumulation (–log10Acc p-value). The pathway 
perturbation was further calculated as an additive measurement of pathway overrepresentation and 
accumulation. The red circle indicates a pathway is significantly perturbed (Bonferroni adjusted p-
value ≤ 0.05), whereas the grey circle indicates non-significance.  
2.4.6 Alternative splicing analysis  
Using Cuffdiff, pair-wise comparisons of differentially expressed transcripts (isoforms) between three 
tissue types (DDfat/CTtis, DDtis/DDfat and DDtis/CTtis) were first conducted. The results were further 
used as input in R package SpliceR46, which enabled us to perform an elaborate genome-wide 
analysis of alternative splicing (AS) including two major aspects: 1) analysis of the AS events in 
disease tissues and controls; 2) identification of isoform switching in disease and controls. 
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First, for each gene annotated by Cufflinks, spliceR constructs the hypothetical pre-RNA based on the 
exon information from all transcripts originating from that gene. Subsequently, all transcripts are 
compared to this hypothetical pre-RNA in a pairwise manner, and AS events are classified and 
annotated.  
Second, for each significant differentially expressed isoform identified by Cuffdiff, spliceR calculates 
an isoform fraction (IF) value, which is calculated as (transcript FPKM/gene FPKM)% to represent the 
contribution of a transcript to the expression of the parent gene. The isoform fraction change dIF (dIF 
= IF condition A / IF condition B), which measures the ratio of IF values between two conditions, was also 
calculated. The isoform switch is defined by a large positive or negative dIF between two conditions 
(|dIf|≥1.5, the same as |log2 dIF| ≥0.6). 
However, to avoid overestimation of the number of functionally relevant isoform switching, the coding 
potential and nonsense mediated decay (NMD) sensitivity were also predicated for each isoform. 
Isoforms were marked NMD-sensitive if the stop codon falls more than 50 nt upstream of the final 
exon-exon junction indicating a pre-mature stop codon (PTC)46.  
Additionally, the IGV tool was used to visualize the exon coverage and splice junctions using the 
aligned reads from Tophat and Cufflinks package60. Alternative splicing events were observed on IGV 
Sashimi plot70. To filter out low-count splicing events, the minimum junction coverage was set to 30 
when Sashimi plots were generated unless elsewhere specified.  
Overall, to identify biologically relevant isoforms in DD pathogenesis, isoform switches in three tissue 
comparisons (DDtis/DDfat, DDtis/CTtis and DDfat/CTtis) were filtered by 5 steps: a) the minimal 
isoform expression cutoff: isoform expression ≥1 FPKM, which supports either tissue type in one 
comparison; b) a minimal threshold for isoform expression fold change:  |log2 (fold change)| ≥ 0.6; c) a 
minimal threshold for isoform fraction change: |log2 dIF| ≥0.6; d) the isoform is marked NMD-
insensitive; 5) the AS events of the isoform can be visualized (or validated) on IGV. 
2.4.7 Heatmap and dendrogram visualization  
For heatmap generation in R (Figure 3-9, 3.19 and 3.20B, 3.26), due to the variable levels of 
expression of individual genes, Z-score normalized gene expression was used71. The Z score was 
determined for any row n by the formula Z = (Sn− Smean)/SD, where Smean is the average signal 
intensity for the gene (across the row) and SD is the standard deviation. The row Z-score normalized 
gene expression was plotted in two color scale with the expression higher than average represented in 
red (Z > +1), the expression lower than average in blue (Z < −1), and average in orange or white (Z = 
0).  
The dendrograms added to the heatmaps were used to measure the hierarchy clustering of samples 
and gene expression profiles using one-minus Spearman's rank. Genes with similar expression or 
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samples with similar gene expression profiles were grouped together and connected by a short line 
between two gene nodes.  
For example, in Figure 3-9, the gene expression clustering of all DEGs in tissue groups is shown in a 
heatmap. Genes with significant expression change in at least one of the three tissue comparisons 
(DDtis/DDfat, DDfat/CTtis and DDtis/CTtis) were first selected. Then the Cufflinks normalized gene 
expression FPKM value for individual tissue sample was Z-score transformed. The Z score 
normalization expresses each gene expression profile as a deviation from the mean in standard-
deviation units and allows the comparison of gene expression patterns whose absolute expression 
levels may differ by orders of magnitude. In summary, this scaled row Z-score value was plotted in 
red–blue color scale with the expression higher than average represented in red (Z > +1), the 
expression lower than average in blue (Z < −1), and the average expression represented in orange (Z 
= 0) (Figure 3-9A).  
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Chapter 3 Results 
3.1 Identification of functional variants at the top GWAS locus at 7p14.1 
The strongest SNP associated with DD is rs16879765, which lies in an intron of EPDR1 and upstream 
of SFRP4 (p=5.6x10–39, Odds Ratio 1.98) at 7p14.1 locus19. In addition, the rs16879765 showed a 
stronger association in the subgroup of patients with a familial predisposition of DD (p=4.7x10–-5, Odds 
Ratio 2.08, n1 = 184) compared to the patients without known family history (n2 = 281) suggesting a 
pivotal role of this locus in the genetically caused pathogenesis of DD72.  
Therefore, we performed a fine mapping study of the 7p14.1 locus by targeted NGS to capture the 
unrecognized functional variants that are supposed to be in LD with the GWAS tag SNP rs16879765. 
The region for target enrichment included a 500 kb haploblock region containing the entire genes 
EPDR1, SFRP4, TXNDC3 and GPR141 as well as part of STARD3NL (Figure 3-1). To identify causal 
variants represented by GWAS SNP rs16879765, we adopted a 'risk haplotype block' guided strategy 
under the hypothesis that the causal variants lie in the risk haplotype tagged by the risk allele of 
rs16879765 (risk allele A, non-risk allele G). In the discovery set (Table 3-1), 96 cases from the 
aforementioned GWAS cohort (Germany and Switzerland)20 with available (or imputed) genotype data 
were selected, including 23 cases homozygous for the risk allele (AA), 51 cases heterozygous (AG) 
and 22 cases homozygous for the non-risk allele (GG).  
 
Table 3-1 The sample set for targeted NGS at 7p14.1 
  
No. of 
patients
AA AG GG
23 51 22
Validation set Sanger sequencing 280
Sample set Method
No. of DD blood DNA samples
Genotype for GWAS leading 
SNP rs16879765 (risk allele 
A; non-risk allele G)
Discovery set Targeted NGS 96
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Figure 3-1 Targeted NGS of a 500 kb region at 7p14.1 
The region for target enrichment included a 500 kb haploblock region containing the entire EPDR1, 
SFRP4, TXNDC3 and GPR141. The GWAS tag SNP rs16879765 is indicated in red diamond. The 
haplomap was constructed based on the pairwise r2 values from Hapmap data for CEU (Central 
European ancestry) population.  
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3.1.1 Targeted NGS and variant calling in the discovery dataset  
DNA was isolated from peripheral blood of 96 DD patients. A 500kb DD-associated locus (chr7: 37.77-
38.27kb) was enriched in these samples and further sequenced by NGS. In total, 41.7 million 
sequencing reads were aligned to the human genome (hg19/GRC37), providing a 77x mean coverage 
across the 500kb targeted region in 96 samples. Variant calling was performed using GATK v1.650 (in 
Varbank 2.16 pipeline) under standard hard filtering parameters and variant quality score recalibration 
according to GATK Best Practices recommendations 
As a result, 12,308 variants were called and 7,242 variants remained after quality control, which were 
then annotated to examine if variants overlapped with bioinformatic features using Varbank 2.16 and 
Ensembl VEP 2.751. The majority of variants were annotated as intronic variants (73%) in the target 
region (Figure 3-2A). Only less than 1% of all variants were coding variants. 
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Figure 3-2 Variant calling and annotation in the 500 kb region at 7p14.1  
(A) A total number of 12,038 variants were called by GATKv1.6 in Varbank pipeline 2.16. After quality 
control and Ensembl VEP 2.7 annotation, 7242 variants remained and were distributed in 7 genes, 28 
transcripts and 51 regulatory features. 
(B) Functional consequences of 7242 variants annotated by Ensembl VEP 2.7 based on Sequence 
Ontology (SO) consequence terms73. Coding variants were included in 'Others'. 
 
 
3.1.2 Functional rare coding variants at 7p1.4 
3.1.2.1 Identification of two rare coding variants on GWAS risk haplotype 
Of the coding variants identified in the discovery dataset, two rare nonsynonymous single nucleotide 
variants (SNVs) in EPDR1, defined as variants with MAF less than 1% in 1KG74 and ExAC75 large 
population database, were predicted to be damaging to protein function by multiple annotation tools, 
such as SIFT59, MutationTaster76, Fathmm77, CADD78 and DANN79 (Table 3-2).  
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Table 3-2 Nonsynonymous variants in EPDR1 identified by targeted NGS at 7p14.1  
 
In the discovery cohort including 96 cases, rs149095633 (C>T, p.P121L) was detected in 4 cases and 
rs37463317 (T>C, p.V102A) was identified in only 1 case. By Sanger sequencing, we successfully 
validated the presence of these two variants and further replicated the findings in a random and 
independent set containing 280 DD blood DNA samples, which were genotyped in a recently reported 
GWAS20. No extra case carrying rs37463317 (T>C, p.V102A) was identified. However, additional 4 
DD patients with the rare variant rs149095633 (C>T, p.P121L) were identified. In total, 8 out of 280 
DD cases carried the heterozygous T allele of rs149095633 (C>T, p.P121L), which leads to an 
enrichment of variant allele frequency in DD patients (n=280) compared to ancestry matched non-
Finnish European (NFE) population in ExAC database75 (n=33,368, Fisher's exact p-value= 2.63E-07, 
Odds Ratio 37.5) (Table 3-2). In addition, all the 9 patients in the validation set with either the 
rs149095633 or rs37463317 rare variant, carried the risk allele A of the GWAS tag SNP rs16879765 
(genotype AA or AG, the LD r2 between rs149095633) (Table 3-2). And both coding SNVs are within 
0.62 kb distance from the GWAS tag SNP rs16879765. 
Taken together, by targeted NGS of a 500kb region at the GWAS risk locus 7p14.1, we identified two 
rare coding variants related to the GWAS risk haplotype (tagged by rs16879765) in DD patients. Both 
coding variants were predicted to be deleterious. In particular, the SNV rs149095633 (P>L) was 
significantly enriched in the DD cohort (n=280).  
3.1.2.2 rs149095633 is a functional rare coding variant in DD 
The SNV rs149095633 (C>T) leads to an amino acid substitution from proline (CCC) to leucine (CTC) 
at position 121 (p.P121L, NP_060019 classical isoform). Leucine is substantially different from proline 
regarding its amino acid properties, for instance, leucine is more hydrophobic80 and polar81 than 
proline (Figure 3-3A). To further assess the in silico significance of the enriched rare variant 
rs149095633 (p.P121L) on EPDR1, we first built a 3-D structure model for the EPDR1 classical 
protein isoform (NP_060019, 224 amino acids) using Gremlin method52,82. The best-predicted 
Codon; Discovery 
set n=96
ExAC 
NFE 
n=33,368
Amino 
acid 
change
SIFT Mutation Taster
Fathm
mMKL CADD DANN  
GWAS SNP 
rs16879765 
genotype
GWAS SNP 
rs16879765 
genotype
MAF MAF p-value Odds ratio 95%CI
cCc>cTC
p.P121L
gTg>gCg
p.V102A
D: deleterious; T: tolerated
CADD score > 10: suggetes deleterious
DANN score (0-1): the closer to 1, the higher the probability of being deleterious
37.5 17.7-79.7
Fisher‘s exact test  
(Validation dataset vs. 
ExAC NFE)
6.6 0.8-49.71 case (AG) 0.03%0.17% 0.14rs374633177 1 case (AG)T D D 22 0.91
4 cases (3AG, 
1AA) 1.40% 0.04% 2.6E-07
Validation dataset 
n=280
8 cases 
(7AG,  1AA)
rs14909563
3
dbSNP ID
 Variant annotation
D D D 31 0.78
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structural model with a high confidence score of 94% is shown in Figure 3-3B. Based on this model, 
the EPDR1 is suggested to be a monomer composed of two β-strands and a connective loop called β-
turn between them. The β-turn conformation is known to be crucial in protein structure by actively 
facilitating cooperative formation of β-strands83. Additionally, β-turns are mostly surface-exposed, 
which makes them well suited for ligand binding and protein-protein or protein-nucleic acid 
interactions, which in turn may modulate protein functions and intermolecular interactions83.  
 
Figure 3-3 The impact of rs149095633 (p.P121L) on EPDR1 protein  
(A) A comparison of the amino acid features between proline and leucine81. Leucine is more 
hydrophobic, and polar than proline. The residual volume of leucine is larger than proline. Leucine is 
commonly found in α-helix, whereas proline is commonly found in turns.  
(B) A 3-D structure model for EPDR1 classical protein isoform (NP_060019) using Gremlin method52,82 
with a high confidence score of 94%. According to this model, EPDR1 protein is suggested to be 
composed of two β strands and a connective loop called β-turn between them. The SNV rs149095633 
leads to an amino acid substitution from proline (CCC) to leucine (CTC) at position 121 (p.P121L) in the 
β-turn domain of EPDR1. 
 
Additionally, EPDR1 (NP_060019) is a 224 amino acid protein including one highly conserved 
Ependymin domain (PF00811) spanning residues 40-223 (http://www.ebi.ac.uk/interpro/protein/-
Q9UM22).  The molecular function of ependymins appears to be related to cell contact phenomena 
involving the extracellular matrix84. The SNV rs149095633 (p.P121L) lies in the Epedymin domain of 
EPDR1. Taken together, the rare coding variant rs149095633 (p.P121L) is likely to affect the protein 
structure and function of EPDR1.  
 35 
Recently, studies suggested that about 15% of human codons are dual-use codons, which specify 
both amino acids and transcription factor (TF) recognition sites85. This suggests the potential for 
coding exons to accommodate regulatory code85.  
Therefore, using Genomatix MatInspector tool53 and TRANSFAC databases54, we examined the effect 
of the rs149095633 missense mutation on TF binding. The MatInspector analysis revealed that the 
minor allele T of rs149095633 (C>T) and DNA sequences around it created a perfect match to the 
core of consensus binding motif of AP-4 (with a high core similarity score 1 and matrix similarity score 
0.864) (Figure 3-4A)53. On the contrary, the same region containing the non-risk allele C of 
rs149095633 did not correspond to any known TF binding motif. The core of the AP-4 consensus 
binding motif (5‘-CAGCTG-3‘, the position of rs149095633*T is shown in bold) is represented in a 
motif logo (Figure 3-4B)54. AP-4 (activating enhancer-binding protein 4) is a highly conserved member 
of the basic helix-loop-helix-zipper family of TFs86. AP-4 has been identified as both a transcriptional 
activator87,88 as well as a transcriptional repressor of gene expression89,90. Therefore, it is possible that 
the allele-specific binding of AP-4 on EPDR1 due to rs149095633 may influence EPDR1 expression.  
To capture whether there is a direct cis-regulatory effect of rs149095633, we performed 
Pyrosequencing, a highly sensitive sequencing method using luminometric detection of released 
pyrophosphate during nucleotide incorporation91 which enables high-accuracy quantification of alleles 
at a position of interest in DNA or RNA samples. In brief, we isolated high quality RNA from available 
DD tissues (n=2) and DD cells (matched DD tissue-derived primary cells, n=2) from two patients 
heterozygous for rs149095633. Blood DNA samples from these two DD patients and four random DD 
patients were used as internal and external controls.  
The RNA from DD tissues and DD cells was further converted in cDNA, which was further used for 
Pyrosequencing. The luminometric signal intensity of allele T and C of rs149095633 in each cDNA (or 
blood DNA) sample was quantified and determined in allele percentage. On average, we observed an 
allelic imbalance at position rs149095633 with a 20% increased expression of risk allele T compared 
to the reference allele C in DD cells (n=2, Figure 3-4C), but not in DD tissues or control blood DNA 
samples. Thus, the rs149095633 missense variant is not only expressed in DD cells, but also appears 
to cause a suggestive allelic imbalance favoring the expression of the risk allele T in DD cells.  
In summary, the rare variant rs149095633 (C>T) in EPDR1 is enriched in the DD cohort (1.4%, 
n=280) compared to a large European population control (0.04%, ExAC NFE, n=33,368). It is 
annotated as a deleterious missense variant (p.P121L). Based on the predicted protein model, the 
substitution of leucine for proline is suggested to affect the EPDR1 protein structure, stability and 
function. Moreover, the cell-type specific allele expression was observed for rs149095633 with higher 
expression of the risk allele (T) compared to the non-risk allele (C), suggesting a contribution to higher 
expression of EPDR1. In addition, the allelic imbalance of rs149095633 may be relevant to the 
function of AP-4 since it creates a consensus-binding site for AP-4. In the future, studies to clarify 
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whether higher expression of rs149095633*T has a direct consequence on EPDR1 expression and 
function and whether AP-4 is a transcriptional activator of EPDR1 are required.  
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Figure 3-4 The allele specific expression of rs149095633  
(A) The SNV rs149095633 changes C to T. Based on Genomatix MatInspector prediction, the minor 
allele T and the DNA sequences around it creates a perfect match to the core of the AP-4 consensus 
binding motif with a high core similarity score (=1) and matrix similarity score (=0.864).  
(B) The core of the AP-4 motif (5‘-CAGCTG-3') is shown in a motif logo, which scales each nucleotide by 
the total bits of information multiplied by the relative occurrence of the nucleotide at the position. The T 
marked by * is the position of rs149095633 T*.  
(C) Left: An allelic imbalance at rs149095633 position was detected by Pyrosequencing, which displayed 
60% allele expression for risk allele T and 40% for the reference allele C in available DD cells (n=2). The 
allelic imbalance on rs149095633 was not observed in blood DNA control samples (n=6, 49% expression 
for allele T and 51% expression for allele C).  
Right: A cartoon representation of allelic imbalance at rs149095633 in DD cells and allelic balance in 
blood DNA controls.  
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3.1.3 A functional common variant in EPDR1 at 7p14.1 
To test whether common variants in LD with GWAS tag SNP are associated with gene expression, we 
manually searched whether SNPs, which are in LD (r2 ≥ 0.2) with rs16879765 in Hapmap CEU 
population23,92, are eQTLs in GTEx database. In eight tissue types (subcutaneous adipose, lung, 
stomach, pancreas, thyroid etc) in GTEx, rs2044831, a common synonymous variant for EPDR1 
(Table 3-3), was identified as a significant eQTL for EPDR1 expression. The allele C of rs2044831 is 
related to increased expression of EPDR1 in all the 8 tissue types (an example of rs2044831 as an 
eQTL for EPDR1 in subcutaneous adipose tissue is shown in Figure 3-5A).  
The common variant rs2044831 is in moderate LD with the GWAS tag SNP rs16879765 in DD 
(r2=0.38 in Hapmap European population)23,92. To test whether rs2044831 is an eQTL for EPDR1 
expression in DD tissues/cells by expression analysis, a large sample size of 200 is required based on 
statistical power analysis25. However, such a sample size of DD tissues/cells was not available in this 
project.  
Therefore, we adopted another method  — Pyrosequencing, which allowed us to determine and 
measure the cis effect of rs2044831 by analyzing the allelic expression using a small sample size of 
DD cells. The RNA of DD cells (n=17) from DD patients heterozygous for rs2044831 (genotype CT) 
was converted in cDNA and used for Pyrosequencing. As shown in Figure 3-5B, a significantly higher 
expression of the DD-risk allele C (54%) was detected compared to non-risk allele T (47%), 
suggesting rs2044831 is a cis-eQTL for EPDR1 expression in DD cells. The risk allele C is likely 
related to increased EPDR1 expression.  
 
Table 3-3 A common regulatory variant identified at 7p14.1 
      
Consequence CADD GTEx Discovery set (n=96)
ExAC NFE 
(n=33,368)
Synonymous
p.I=
CADD score > 10: suggests deleterious
LD r2 with GWAS 
tag SNP 
rs16879765  
0.38         
(Hapmap CEU)
dbSNP ID Uniprot
Risk 
allele in 
DD
Non risk 
allele in 
DD
rs2044831 EPDR1 C T Cis-eQTL in 8 tissue types 30% 20%
Allele frequency for risk 
allele C in DDVariant annotation
18.8
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Figure 3-5 rs2044831 is an eQTL candidate for EPDR1 in DD cells 
(A) rs2044831 is a an eQTL for EPDR1 in subcutaneous adipose in GTEx database. The rs2044831*C 
allele is associated with increased expression of EPDR1 compared to the rs2044831*T allele in 
subcutaneous adipose as well as other 7 tissue types. 
 (B) Using Pyrosequencing, a significant allelic imbalance was observed for rs2044831 in DDcells (n=17, 
student’s t-test p-value=1.08E-05, normality was tested by Shapiro-Wilk test). Higher expression of DD-
risk allele C (54%) was detected compared to non-risk allele T  (47%). 
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3.2 Prioritization of candidate genes carrying rare variants in DD  
To test whether genome-wide rare variants contribute to the high genetic predisposition of DD, we 
performed whole exome sequencing (WES) of DD patients in a pilot study.  
Low-frequency coding variants have long been known to contribute to family-based complex diseases 
including early-onset forms93 or Mendelian forms94 of complex diseases. Family-based WES of 
affected individuals and their unaffected family members has become a crucial tool to evaluate the 
contribution of rare variants to the disease trait in the family and unravel new candidate genes and 
pathways with relevance to molecular pathogenesis of common disorders95. Such study design is 
powerful and cost-effective but challenging to be implemented for DD. Because most of the DD cases 
are late-onset and consequently multi-generation pedigrees for DD were hardly available. 
This leaves us to choose another strategy — the population-based strategy for which non-related 
cases were sequenced to identify rare variants in DD with effect on population level. However, the 
statistical power of rare variant association tests is usually very low unless the sample size or variant 
effect size are very large96. Moreover, like many complex disorders, DD susceptibility is likely to be 
associated with the effects of multiple variants and gene-gene interactions in contrast to monogenic 
disorders. 
Therefore, in this small-size WES pilot study, instead of purely prioritizing variants based on their 
variant score (frequency and deleteriousness), I used a phenotype-driven method to prioritize 
functional candidate genes using a combination of disease phenotype ontology, gene intolerance 
scores and variant scores. In total, 12 candidate genes carrying rare deleterious variants were 
identified in DD patients.   
3.2.1 Characteristics of WES study cohort 
Two major criteria were used to select DD patients for WES. The first criterion was to select DD 
patients with an early age of first operation. The second was to select patients with a known family 
history of DD (at least one family member affected within two generations).  
Accordingly, 40 DD patients were selected with high genetic predisposition possibilities (Table 3-4). 
The average age of these 40 patients is 44 years, which is much lower than the typical manifestation 
age 55-64 years97. Moreover, 39 patients have a family history of DD and 30 patients have both hands 
affected. Blood DNA was isolated from 40 DD patients and sequenced on Illumina HiSeq 2000.  
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Table 3-4 The DD cohort for WES 
      
   
Patient ID Gender Age at 1st DD operation Family history Hand affected Country of origin
DDpatient1 m 46 both parental lines both DE
DDpatient2 f 40 fatherside related both DE
DDpatient3 m 44 fatherside related both DE
DDpatient4 m 48 fatherside related both DE
DDpatient5 f 68 motherside related both DE
DDpatient6 m 41 motherside related both DE
DDpatient7 m 42 motherside related both DE
DDpatient8 m 47 motherside related both DE
DDpatient9 m 48 motherside related both DE
DDpatient10 m 45 positive both DE
DDpatient11 m 41 uncle both DE
DDpatient12 m 37 father both DE
DDpatient13 m 44 father both DE
DDpatient14 f 48 father both DE
DDpatient15 m 44 father both DE
DDpatient16 m 44 father left DE
DDpatient17 m 49 father right DE
DDpatient18 m 50 father both DE
DDpatient19 m 51 father, brother right DE
DDpatient20 m 43 father, brother, sister both DE
Continued on the next page
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Patient ID Gender 1st Operation  age Family history Hand affected Country of origin
DDpatient21 m 45 father, grandmother both DE
DDpatient22 f 47 father, mother left DE
DDpatient23 m 35 father, mother, brother, uncle (fatherside) both DE
DDpatient24 m 30 father, mother, sister both DE
DDpatient25 m 43 fatherside related both DE
DDpatient26 m 44 grandfather (fatherside) both DE
DDpatient27 m 47 grandfather (fatherside) right DE
DDpatient28 f 41 grandfather (motherside) left DE
DDpatient29 m 45 grandfather (motherside) both DE
DDpatient30 m 48 grandmother both DE
DDpatient31 m 40 granduncle left DE
DDpatient32 f 34 mother both DE
DDpatient33 m 50 mother both DE
DDpatient34 f 48 mother, brother left DE
DDpatient35 m 48 mother, grandfather (motherside) both DE
DDpatient36 m 34 motherside related both DE
DDpatient37 m 39 positive both DE
DDpatient38 m 51 positive both DE
DDpatient39 m 44 uncle (motherside) right DE/PL
DDpatient40 m 28 not reported right DE
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3.2.2 Functional annotation of variants in WES data 
A two-step integrative approach was applied to annotate variants and prioritize disease-causing 
candidate genes (see Figure 3-6 and Figure 3-7).  
The high-confidence variants (n=99,323) called by GATK were annotated using Annovar 
(2016Feb01)58. Variants were classified based on their functional consequences. Missense, 
nonsense, and splicing variants were selected among the identified variants and further filtered for 
conservation using conservation information in 46 vertebrate species98. To reduce the false-discovery 
rate, only variants not in segmental duplication regions were selected since reads mapped to these 
regions can match to other regions of the genome99. 
Of the remained 20,750 variants, 9263 variants were identified as rare variants, which were defined as 
MAF less than 1% in both 1KG and large population databases including ExAC121K75 and NHLBI-
ESP6500 (http://evs.gs.washington.edu/EVS). 
The functional effect of rare variants was further assessed by SIFT prediction score59. In total, 3919 
rare variants (42%) in 3088 genes were considered as deleterious variants according to their SIFT 
scores (SIFT < 0.05) (Figure 3-6A). As shown in Figure 3-6B, 94% deleterious variants were 
nonsynonymous variants. About 86% of deleterious variants were found only once (Allele count =1) in 
40 samples (Figure 3-6C), suggesting not only that they were heterozygous variants, but also the 
difficulty to associate a single genetic variant with DD. 
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Figure 3-6 Annotation of functional variants in WES data of 40 DD patients 
(A) Variant annotation steps using Annovar (2016Feb01). 
(B) The distribution of 9263 rare variants based on functional consequences or (C) allele counts. 
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3.2.3 Identification of genes related to the DD phenotype  
Though the genes that contribute to DD etiology are largely unknown, DD patients display a similar 
and well-defined phenotype with progressive fibrosis in the palmar connective tissue, which further 
leads to finger contracture. 
Therefore, here I applied a phenotype-based strategy to identify candidate genes for DD using 
Phenolyzer29, which involves computation tools for three key steps 1) associate the input human 
phenotypic ontology (HPO) terms100 with known human diseases; 2) associate genes causing (or 
predicted as disease-causing) known diseases with the HPO terms; 3) integrate multiple features to 
score and prioritize all candidate genes.  
Here, three HPO terms were used to represent the DD phenotype, which are 'flexion contracture of 
finger', 'connective tissue', and 'fibrosis'. Only 88 genes predicated as highly related to three DD 
phenotype terms (defined as a raw Phenolyzer score ≥ 1) were considered in the following analysis. 
Then the set of 1774 genes with gene burden greater than 2 (carrying at least 2 deleterious rare 
variants or variant allele accounts appeared more than 2 times) was compared with 88 genes related 
to DD phenotype. As a result, an overlapping set of 30 genes was considered as DD phenotype-
related genes carrying rare genetic variants (Figure 3-7A). 
3.2.4 Identification of genes intolerant to mutations in the palmar tissue 
To assess whether there is an enrichment of genes predicted to be involved in DD pathogenesis, gene 
set enrichment analysis (GESA) on gene intolerance was applied to the above 30 genes using the 
gene intolerance score EvoTol63, which identifies an intolerant gene as a gene containing an 
excess of mutations that, on the protein space, are not favored by evolution compared to other 
genes with the same number of mutations. To faithfully evaluate the tissue-specific impact, the 
intolerance ranking was limited to genes expressed in the palmar part of hand — the tissue affected 
by DD. Accordingly, an enrichment of pathogenicity in palmar tissue was determined (FDR q-value 
<0.001) by WGPA-GSEA tool61,62, suggesting the overrepresented pathogenicity of the 30 genes 
(Figure 3-7B) in palmar part of hands. The class of pathogenic genes includes 12 genes, which were 
identified as the top 25% intolerant genes in the palm, suggesting a functional role of these genes in 
the hand palm (Figure 3-7C). 
In conclusion, in the DD cohort for WES, 12 genes carrying rare deleterious variants were suggested 
as DD phenotype-related candidate genes (Table 3-5). Mutations in these genes may contribute to the 
pathogenicity in hand palmar part. Of note, this WES pilot study was an exploratory study. Functional 
effects of the candidate genes in DD pathogenesis should be tested systematically in the future. 
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Figure 3-7 The prioritization of pathogenic candidate genes related to DD phenotypes  
(A) 1774 genes with gene burden more than 2 were compared with 88 genes highly related to DD 
phenotype (Phenolyzer score ≥ 1). An overlapping set of 30 genes was identified.  
(B) An enrichment of pathogenicity in palmar tissue for the above 30 genes was determined by WGPA-
GSEA tool. 
(C) Among 30 DD phenotype-related genes, 12 genes were predicted as the top 25% genes, which are 
intolerant to mutations in hand palmar part based on EvolTol score. 
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Table 3-5 12 candidate genes related to the DD phenotype 
   
Gene EvoTol
Phenolyzer 
score *  
(0.0001 - 
5.7)
Gene 
burden dbSNP138 Start End Ref Alt
Allele 
count 
. 48608296 48608296 G A 1
rs139434755 48629340 48629340 G A 1
rs35623035 48630252 48630252 G A 2
rs139064549 103354135 103354135 G C 2
rs141978499 103544374 103544374 C G 1
rs41306397 137591755 137591755 C T 1
rs199735010 137694750 137694750 C T 1
rs368305377 137702117 137702117 C T 1
rs61739195 137708884 137708884 C T 1
. 94055143 94055143 G A 1
. 94057101 94057101 A C 1
9 ROR2 9.28% 1.2 3 rs35852786 94487187 94487187 C T 3
rs114260147 149359938 149359938 C G 1
rs104893915 149359991 149359991 C T 1
. 58141747 58141747 T C 1
rs116826041 58145348 58145348 T C 1
rs149638325 58148895 58148895 C T 1
rs373336251 55240795 55240795 G A 1
rs201830126 55268023 55268023 G A 1
rs61756429 111608216 111608216 T A 1
rs115287852 111612783 111612783 T C 1
rs1801166 112175240 112175240 G C 1
rs141010008 112178781 112178781 C T 1
5 FGF1 21.06% 1.2 2 rs17223632 141993631 141993631 C T 2
. 37879585 37879585 A C 1
rs55943169 37884176 37884176 C A 1
* Phenolyzer score: the higher, the more evidence for the association between a candiate gene and a phenotype
Gene annotation
4
5.58%
11
17
1.2
1.3
1.4
1.2
3.6
1.4
COL1A2 
COL5A1
PPP2R1B
ERBB2
COL11A1
1.2
1.0
7
7
9
SLC26A2
EGFR
FLNB
0.32%
0.86%
0.04%
0.24%5
5
COL7A1
APC
3
4
3
2
2
2
Exome data
Chr
2
2
0.27%
3.48%
20.26%
15.02%
1.4
1.4
Rare variant annotation
1
3
3
2
10.76%
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3.2.5 Pathway overrepresentation analysis of candidate genes 
To interpret the biological signatures of the above 12 candidate genes, gene ontology (GO)101 and 
pathway overrepresentation was analyzed by Enrichr tool65.  
The GO is a structured, controlled vocabulary of terms providing computational or experimental 
knowledge on gene product properties. For the set of 12 candidate genes, three main GO categories 
were analyzed including overrepresented biological process, cellular component 
and molecular function. 101 
GO analysis revealed that the top overrepresented term ranked by lowest p-value in the cellular 
components is 'fibrillar collagen trimmer'. The affected molecular functions were mostly involved in 
'growth factor binding' and 'cell-extracellular matrix (ECM) interactions' (including 'ECM structural 
constituent', 'cell adhesion molecule binding', 'glycoprotein binding' and 'integrin binding'). The 
significantly affected biological processes were related to metabolic catabolic processes of 
macromolecules, including collagen, and the regulation of epithelial cell proliferation (Table 3-6).  
Using the KEGG pathway resource66, 18 significantly overrepresented pathways (Bonferroni adjusted 
p-value ≤ 0.05) were identified. The top 10 pathways include the 'Hippo signaling network' (including 
the child Hippo pathway, Wnt/ß-catenin pathway and TGFß pathway), the 'PI3K-Akt pathway', 'Focal 
Adhesion', 'Regulation of Actin Cytoskeleton', 'Protein Digestion and Absorption’ and 'Pathways in 
Cancer' etc (Table 3-7).  
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Table 3-6 Overrepresented GO terms for 12 candidate genes  
 
 
Index GO Molecular Function 2015 Overlap* Adjusted p-value Z-score
Combined 
score
1 growth factor binding 4 2.0E-04 -2.4 20.2
2 platelet-derived growth factor binding 2 6.1E-04 -2.4 17.9
3 receptor signaling protein tyrosine kinase activity 2 6.1E-04 -2.3 17.2
4 transmembrane receptor protein kinase activity 3 6.1E-04 -2.2 16.4
5 extracellular matrix structural constituent 3 6.1E-04 -2.2 16.2
6 transmembrane receptor protein tyrosine kinase activity 3 6.1E-04 -2.2 16.1
7 protein tyrosine kinase activity 3 2.2E-03 -2.3 14.0
8 cell adhesion molecule binding 3 3.2E-03 -2.3 13.1
9 glycoprotein binding 2 1.7E-02 -2.2 9.0
10 integrin binding 2 2.2E-02 -2.2 8.4
Index GO Biological Process 2015 Overlap Adjusted p-value Z-score
Combined 
score
1 multicellular organismal macromolecule metabolic process 4 1.2E-04 -2.2 19.8
2 collagen metabolic process 4 1.2E-04 -2.2 19.7
3 collagen catabolic process 4 1.2E-04 -2.2 19.7
4 multicellular organismal catabolic process 4 1.2E-04 -2.2 19.6
5 multicellular organismal metabolic process 4 1.2E-04 -2.2 19.6
6 collagen fibril organization 3 4.7E-04 -2.5 19.3
7 extracellular matrix disassembly 4 2.2E-04 -2.2 18.3
8 cellular component disassembly 5 4.7E-04 -2.3 17.9
9 regulation of epithelial cell proliferation 4 2.9E-03 -2.4 14.3
10 Fc-epsilon receptor signaling pathway 3 2.4E-02 -3.8 14.0
Index GO Cellular Component 2015 Overlap Adjusted p-value Z-score
Combined 
score
1 fibrillar collagen trimer 4 5.7E-08 -2.5 42.0
2 collagen trimer 4 3.7E-05 -2.2 22.2
3 extracellular matrix part 4 8.9E-05 -2.1 19.7
4 endoplasmic reticulum lumen 4 1.4E-04 -2.2 19.2
5 extracellular matrix 4 2.6E-03 -2.2 13.0
6 basement membrane 2 2.3E-02 -2.2 8.2
7 extracellular region 5 5.1E-02 -2.5 7.3
8 adherens junction 3 4.5E-02 -2.3 7.0
9 anchoring junction 3 4.5E-02 -2.2 6.9
10 basolateral plasma membrane 2 4.8E-02 -2.0 6.1
* Overlap: Number of genes overlapped between 12 candidate genes and genes in a GO term
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Table 3-7 Overrepresented pathways for 12 candidate genes  
 
  
Index KEGG pathway 2016 Overlap* Adjusted p-value Z-score
Combined 
score
1 Protein digestion and absorption 4 3.3E-04 -1.7 13.8
2 Endometrial cancer 3 1.4E-03 -2.0 12.8
3 Focal adhesion 4 2.4E-03 -1.9 11.3
4 PI3K-Akt signaling pathway 4 1.3E-02 -2.0 8.7
5 Pathways in cancer 5 1.3E-02 -2.0 8.5
6 Proteoglycans in cancer 3 1.6E-02 -1.8 7.5
7 Non-small cell lung cancer 2 1.6E-02 -1.8 7.3
8 Bladder cancer 2 1.3E-02 -1.7 7.2
9 Hippo signaling pathway 3 1.3E-02 -1.6 7.2
10 Regulation of actin cytoskeleton 3 1.6E-02 -1.7 7.0
* Overlap: Number of genes overlapped between 12 candidate genes and genes in a KEGG pathway
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3.3. Global gene expression profiling in DD  
3.3.1 Study subjects and sampling for RNA-seq 
To obtain an in-depth understanding of the transcriptional regulation in DD, we performed a 
comprehensive transcriptomic analysis using DD biopsy samples from 11 DD patients in the WES 
cohort (described in session 3.2.1).  
Two types of tissue samples were collected from a single DD patient including the affected palmar 
nodule tissue (DDtis) and the matched perinodular fat (DDfat). Additionally, the primary cells derived 
from DDtis were also collected and used as the in vitro cell model for DD (DDcell). 
The control samples were obtained from 11 patients affected with carpal tunnel (CT) syndrome. The 
CT syndrome is a peripheral neuropathy due to compression of the median nerve as it travels through 
the wrist at the CT. All 11 CT patients involved in this study have no diagnosis of DD and no reported 
familial history of DD, therefore, are considered as healthy controls without DD. Palmar connective 
tissues (CTtis), mainly composed of fat, were collected during carpal release and used as external 
healthy tissue control for DDtis. The cells collected from CTtis (CTcell) were used as external healthy 
cell control for DDcell.  
Additionally, in order to minimize the cofounding bias between case and control, 11 DD patients and 
11 CT controls were carefully selected by matched age at sample collection (mean age: 60 and 61 
separately) and country of origin (Germany) (Table 3-8). In total, we analyzed 50 transcriptomes using 
high quality RNA isolated from DD relevant samples (DDtis, DDfat and DDcell) and control samples 
(CTtis and CTcell).  
Table 3-8 Study subjects and samples for RNA-seq 
   
Subjects
Family 
histroy of 
DD
Age at 1st 
DD 
operation
Hands 
affected 
with DD
Primary 
cells
Mean age 
at sample 
collection
Country of 
origin Gender
9 male
 2 female
11 male
0 female
10 CTtis 11 CTcell 61 DE11 CT Controls
not 
reported negative - -
11 DD 
Cases
Matched cofounding factors  
Exome 
data
Genetic susceptibility to DD
Tissues
No. of samples collected for 
RNAseq
9 DDfat 10 DDtis 10 DDcell 60 DEyes 46 both yes
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3.3.2 Differentially expressed genes (DEGs) in DD related tissues 
We first conducted pair-wise comparisons of differentially expressed genes (DEGs) between three 
tissue types, including DDfat compared to CTtis (abbreviated as DDfat/CTtis), DDtis vs. DDfat 
(DDtis/DDfat) and DDtis vs. CTtis (DDtis/CTtis).  
To determine significantly DEGs, the following filtering approach was applied (Figure 3-8A). On a 
global scale, a) 769 significant DEGs were identified in DDfat/CTtis; b) 2777 significant DEGs in 
DDtis/DDfat; c) 3597 significant DEGs in DDtis/CTtis. These DEG sets were used for downstream GO 
features and pathway analyses. The distribution of gene expression fold change in each comparison is 
shown in a volcano plot (expression fold change vs. p-values) in Figure 3-8B.  
The gene expression clustering of all DEGs is shown in a heatmap in Figure 3-9A. Overall, more 
genes were significantly upregulated in DDtis compared to two controls (DDfat and CTtis). 
Additionally, the gene expression profiling in DDtis classified the DD samples into two subgroups: one 
subgroup of DDtis samples from 4 patients and the other subgroup of DDtis from 6 patients.  
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Figure 3-8 The identification of DEGs between tissue groups  
(A) Filters applied on gene expression data in 3 comparisons: (a) DDfat vs CTtis; (b) DDtis vs. DDfat; (c) 
DDtis vs CTtis.  
(B) Volcano plots of distribution of DEGs in each comparison, where log2 fold change (x-axis) is plotted 
against −log10 FDRadjusted q-value (y-axis). Significant DEGs are colored in red, while the rest are 
colored in black.  
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Figure 3-9 A heatmap representation of DEGs in tissue groups 
(A) Gene expression profilings of DDtis, DDfat and CTtis. Each row represents a gene that is significant 
differentially expressed in any of the 3 comparisons (DDtis/DDfat, DDtis/CTtis and DDfat/CTtis). Each 
column represents an individual tissue sample.  
The expression of each gene (FPKM value) was normalized by the Z-score to gain insight into the gene 
expression patterns in three tissue groups (DDtis, DDfat and CTtis). This scaled row Z-score value is 
plotted in red–blue color scale with expression higher than average represented in red (Z > +1), 
expression lower than average in blue (Z < −1), and average in orange (Z = 0).  
(B) A zoom in to the gene expression profiling of DDfat and CTtis. The gene expression (FPKM value) 
higher than average is represented in red (Z > +1), expression lower than average in blue (Z < −1), and 
average in white (Z = 0).  
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3.3.3 Gene Ontology enrichment of DEGs in DD related tissues 
To interpret the function of the DEGs, we first queried enriched GO terms101 using iPathwayGuide in 
three tissue comparisons: a) DDfat/CTtis; b) DDtis/DDfat and c) DDtis/CTtis.  The common enriched 
GO terms among three comparisons are shown in Venn diagrams (Figure 3-10).  
For example, in GO category biological processes, there were 265 GO terms only shared between 
DDtis/DDfat and DDtis/CTtis, which are likely related to distinctive biological processes in DDtis 
(Figure 3-10A). The GO biological processes shared in both DDtis/CTtis and DDtis/DDfat were ranked 
by GO p-values in DDtis/CTtis (from low to high). The top-10 GO terms represented in a heatmap, 
which reveals significant involvement of ECM in DD, e.g. 'ECM organization', 'ECM disassembly', 
'collagen catabolic processes', and 'collagen fibril organization' (Figure 3-10A and Table 3-9).  
The same analysis was performed on GO molecular function and GO cellular components (Figure 3-
10B and C, Table 3-9). A remarkable feature in the GO molecular function analysis was that the 9 top 
GO terms in both DDtis/CTtis and DDtis/DDfat (ranked by GO p-values in DDtis/CTtis from low to 
high) were involved in either extracellular structural constituent or molecule binding (including 
'collagen binding', 'integrin binding', 'actin binding', 'actin filament binding',  'calcium ion binding', 
'heparin binding', 'growth factor binding', and 'phosphatidylserine binding'). With respect to GO cellular 
component, the most significant GO term in both DDtis/CTtis and DDtis/DDfat was 'extracellular 
space' supporting the pivotal involvement of ECM in DD pathogenesis.  
Taken together, this GO term analysis in all three comparisons (DDfat/CTtis, DDtis/DDfat and 
DDtis/CTtis) reveals significant functional alterations of genes involved in ECM components, dynamics 
and function in DDtis, which is in line with the important role of ECM in connective tissue.  
 
 
 
 
 56 
 
Figure 3-10 Overrepresented GO terms for DEGs in tissue comparisons 
The Venn diagrams highlight the common enriched GO terms among three comparisons. The most 
significant 10 GO terms only shared between DDtis/DDfat and DDtis/CTtis were represented in heatmaps 
(ranked by the –log10pvalue in DDtis/CTtis, the most significant on top). Each row represents a GO term. 
Each column represents a comparison (DDfat/CTtis, DDtis/DDfat and DDtis/CTtis). The intensity of the 
shading indicates the significance of the GO term. Each blue box has a p-value of ≤0.05; white box has a 
p-value >0.05 and is not significantly altered. See details in Table 3-9.   
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Table 3-9 Overrepresented GO terms for DEGs in tissue comparisons 
 
#genes 
(DE/All)  p-value
#genes 
(DE/All)  p-value
#genes 
(DE/All)  p-value
1 ECM organization 162/298 4.20E-14 186/301 1.10E-15 47/284 1.20E-05
2 ECM disassembly 55/96 1.80E-11 64/97 1.40E-11 13/87 3.20E-02
3 Cell adhesion 348/927 2.60E-11 454/937 8.60E-11 135/908 1.00E-03
4 Collagen catabolic process 38/56 5.10E-12 40/57 6.80E-10 7/49 5.00E-02
5 Platelet degranulation 33/67 6.70E-06 43/66 5.80E-09 15/66 2.90E-04
6 Signal transduction 1028/3482 2.30E-02 1331/3501 4.00E-08 327/3407 1.00E-02
7 Positive regulation of cell migration 114/298 8.50E-05 155/303 1.10E-07 32/291 .
8 Collagen fibril organization 24/34 1.30E-08 25/34 2.70E-07 2/30
9 Negative regulation of cell proliferation 161/472 8.00E-05 209/476 3.60E-07 68/459 1.90E-05
10 Chondrocyte development 16/22 2.00E-04 18/22 9.20E-07 4/22 .
Continued on the next page
DDtis/DDfat DDtis/CTtis DDfat/CTtis
GO term Biological 
Processes
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#genes 
(DE/All)  p-value
#genes 
(DE/All)  p-value
#genes 
(DE/All)  p-value
1 Calcium ion binding 140/371 4.20E-10 177/377 2.40E-12 62/372 6.50E-12
2 Heparin binding 55/105 1.50E-10 67/107 3.30E-12 29/98 2.60E-12
3 Growth factor activity 40/81 3.80E-07 52/84 1.60E-09 14/74 2.90E-04
4 Integrin binding 42/81 3.20E-08 50/81 3.80E-09 10/79 3.40E-02
5 Actin binding 119/280 1.70E-07 146/284 3.70E-08 27/277 .
6 ECM structural constituent 30/45 6.30E-08 31/46 2.00E-07 7/41 1.70E-02
7 Cytokine activity 37/88 9.60E-05 50/89 2.80E-07 17/78 6.00E-03
8 Actin filament binding 38/82 5.20E-06 47/83 4.60E-07 10/82 4.30E-02
9 Phosphatidylserine binding 14/22 7.30E-05 17/20 5.80E-07 5/22 1.30E-02
10 Collagen binding 34/57 5.30E-08 36/59 8.70E-07 13/57 6.50E-04
#genes 
(DE/All)  p-value
#genes 
(DE/All)  p-value
#genes 
(DE/All)  p-value
1 Extracellular space 295/698 1.00E-24 378/709 1.00E-24 136/678 4.10E-23
2 Integral component of membrane 881/2696 1.80E-16 1132/2737 2.30E-22 265/2634 5.50E-04
3 Integral component of plasma membrane 284/763 3.40E-13 370/772 1.80E-20 110/739 2.70E-13
4 Proteinaceous ECM 155/260 1.00E-24 165/262 1.80E-20 52/237 1.50E-10
5 Plasma membrane 874/2580 1.20E-12 1116/2613 9.50E-18 304/2529 7.90E-10
6 Extracellular exosome 571/1900 6.20E-11 730/1919 6.20E-15 187/1903 3.40E-08
7 Extracellular region 908/2669 4.30E-10 1144/2704 5.70E-14 316/2623 2.30E-06
8 Cell surface 162/445 5.20E-07 227/451 3.80E-13 77/439 4.40E-08
9 Endoplasmic reticulum lumen 76/137 4.70E-14 81/136 1.90E-12 12/130 .
10 Platelet alpha granule lumen 20/35 3.00E-05 27/35 1.70E-08 10/34 6.20E-05
DDtis/DDfat DDtis/CTtis DDfat/CTtis
DDtis/DDfat DDtis/CTtis DDfat/CTtis
GO Molecular 
Function
GO Cellular 
Components
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3.3.4 Pathway perturbation analysis using DEGs in DD related tissues 
To study the specific pathways associated with DD, a third generation pathway topology (PT)-based 
pathway perturbation analysis68 via a combination of over-representation analysis and pathway 
accumulation was performed using iPathwayGuide on aforementioned DEG sets (Figure 3-11). For 
over-representation analysis, the number of DEGs involved in a pathway was compared between two 
tissue groups. For pathway accumulation analysis, the significance of a particular DEG to a pathway 
was considered in determining the overall impact on the pathway by examining all annotated 
functions/interactions of the gene in KEGG pathway databases66. The calculated pathway perturbation 
is an additive measurement of pathway overrepresentation and accumulation. Bonferroni adjusted p-
value 0.05 on pathway perturbation was used as a cut-off to identify significantly perturbed pathways.  
Figure 3-11 Perturbed pathways in tissue comparisons 
The scatter plots represent the pathways (in red) significantly perturbed in three comparisons: (A) 
DDfat/CTtis; (B) DDtis/DDfat; (C) DDtis/CTtis. The pathway perturbation is an additive measurement of 
pathway overrepresentation and accumulation. The x-axis represents the significance of pathway 
overrepresentation (–log10OVA p-value). The y-axis represents the significance of pathway 
accumulation (–log10Acc p-value). Bonferroni adjusted p-value 0.05 on pathway overrepresentation and 
accumulation was used as a cut-off for identifying significant perturbed pathways. (Continued on the next 
page) 
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The bootstrap diagram shows the distribution (mean=0, stdev=1) of expected accumulated perturbation 
values based on the observed data for the selected pathway. The red line indicates where the actual 
observed values lie in the distribution of expected results. The further away from the mean, the less likely 
the observed values are due to random chance.  
 
3.3.4.1 Perturbation of the Hippo signaling pathway in DDfat/CTtis 
In the comparison DDfat/CTtis, the most significantly perturbed pathway (with the lowest p-value for 
pathway overrepresentation and accumulation) was the Hippo network (Figure 3-11A, x- and y-axis 
represent the significance of overrepresentation and accumulation separately). A bootstrap diagram 
was also shown separately, which displays the distribution (mean=0, stdev=1) of expected 
accumulation values based on the observed data. 2,000 iterations were used to construct the 
distribution. The red line indicates where the actual observed values lie in the distribution of expected 
results. The further away from the mean, the more likely the observed value is not due to random 
chance.  
Of note, the KEGG Hippo network is designated as a 'parent' network composed of the 'child' Hippo 
signaling pathway (also named as the YAP/TAZ pathway since YAP/TAZ are the major effectors of the 
Hippo signaling pathway) and two interactive pathways  — the Wnt/ß-catenin signaling pathway and 
TGFß pathway (shown in Figure 3-12B).  
In DDfat/CTtis, four genes (LLGL2, RASSF6, WWC1 and INADL) involved in the 'child' Hippo pathway 
were downregulated (Figure 3-12A), suggesting an inactivation of the 'child' Hippo pathway. Inhibition 
of downstream transcriptional activators, YAP/TAZ, is the major target of the 'child' Hippo signaling 
pathway. Therefore, the downregulation of these four genes may activate YAP/TAZ, as suggested by 
iPahtwayGuide perturbation computation, which represents the propagation of the effect of upstream 
gene expression change by considering interactions between different genes (Figure 3-12B, genes in 
red indicates activation or increased expression, while genes in blue indicates inhibition or decreased 
expression. 
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Figure 3-12 The Hippo network is the most significantly perturbed pathway in DDfat/CTtis 
(A) The expression fold change of DEGs in the KEGG Hippo network in DDfat/CTtis. 
(B) The perturbation on genes involved in the KEGG Hippo network due to DEGs in DDfat/CTtis. Genes 
in red indicates activation or increased expression, while genes in blue indicates inhibition or decreased 
expression. The darker color indicates the stronger perturbation. 
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Moreover, the expression four Wnt ligand genes (WNT6, WNT10A, WNT10B and WNT9A), two 
Frizzled receptor genes (FZD1 and FZD2) involved in the upstream of the Wnt signaling pathway was 
also increased in DDfat compared to CTtis (Figure 3-12A), leading to perturbation on the downstream 
effector ß-catenin and transcription factors TCF/LEF (Figure 3-12B).  
In addition, the expression of three genes in the Bone Morphogenetic Protein (BMP) family and a BMP 
receptor (BMP7, BMP4, GDF6 and BMP1B) was increased, while, the expression BMP5 was 
decreased in DDfat compared to CTtis. The increased expression of BMPs, which are upstream 
regulators to the TGFβ, is likely to induce the TGFβ pathway. 
In summary, though the DDfat and CTtis were considered as non-disease adipose tissue for DD in the 
past, significant DEGs in DDfat/CTtis were identified and suggested to be involved in three interactive 
pathways (including the YAP/TAZ signaling pathway, the Wnt/ß-catenin signaling pathway and the 
TGFß pathways). By pathway perturbation analysis on all DEGs in the DDfat/CTtis comparison, the 
KEGG parent network  — the Hippo network was identified as the most perturbed pathway with the 
lowest p-value (Bonferroni adjusted p-value = 0.001). These findings reveal, for the first time, 
perturbation on pathways in perinodule fat tissue (DDfat) and the potential role of the Hippo network in 
DD pathogenesis.  
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3.3.4.2 Perturbation of the ECM-receptor interactions in DDtis 
The pathway perturbation analysis was also conducted using DEGs in DDtis/DDfat and DDtis/CTtis. 
The ECM-receptor interaction was identified as the most significant perturbed pathway in both 
comparisons (Figure 3-11B and C).  
About 80% of DEGs involved in the ECM-receptor interactions pathway showed increased expression 
in DDtis compared to either internal control (DDfat) or external control (CTtis) (Figure 3-13A and 
3.14A). The common upregulated DEGs in the ECM-receptor interactions included genes encoding 
the ECM structural and functional macromolecules (COL1A1, COL1A2, COL6A1, COL6A2, COL6A3, 
FN1 and THBS2 etc., which maintain cell/tissue structure and function), transmembrane integrins 
(ITGB1, ITGA8, ITGA10 etc, which function as mechanoreceptors and provide force-transmitting 
physical links between the ECM and cells) as well as the cytoskeleton proteoglycans (such as SDC2 
and SV2A) and other cell-surface-associated components (for instance, CD44). The increased 
expression of these genes can strongly influence interactions between cells and ECM, 
directly/indirectly leading to cellular activities such as adhesion, migration, differentiation, proliferation, 
and apoptosis66.  
The most significant downregulated DEG in both comparisons (DDtis/DDfat and DDtis/CTtis) is CD36 
(log2FC value -3.4 and -3.6 separately). Recent studies have revealed a causative role of CD36 
downregulation in suppressing the ECM deposition and in promoting the protumorigenic phenotypes 
of tumor stromal microenvironment102. Therefore, the reduced expression of CD36 in DDtis (vs. DDfat 
or CTtis) opens up the question whether there is also an influence of the DDtis on its 
microenvironment — DDfat, the adipose tissue adjacent to DDtis.  
Overall, these results suggest the ECM-receptors interactions pathway is strongly related to the 
biochemical and functional characteristics of DD nodules. 
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Figure 3-13 The ECM-receptor interactions pathway is the most significantly perturbed pathway in 
DDtis/DDfat  
(A) The gene expression fold change of DEGs in the KEGG ECM-receptor interactions pathway 
(B) The perturbation calculation on genes involved in the KEGG ECM-receptor interactions pathway due 
to DEGs in DDtis/DDfat. Genes in red indicates activation or increased expression, while genes in blue 
indicates inhibition or decreased expression. The darker color indicates the stronger perturbation. 
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Figure 3-14 The ECM-receptor interactions pathway is the most significantly perturbed pathway in 
DDtis/CTtis 
(A) The gene expression fold change of DEGs in the KEGG ECM-receptor interactions pathway 
(B) The perturbation calculation on genes involved in the KEGG ECM-receptor interactions pathway due 
DEGs in DDtis/CTtis. Genes in red indicates activation or increased expression, while genes in blue 
indicates inhibition or decreased expression. The darker color indicates the stronger perturbation. 
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3.3.4.3 Summary of all overrepresented KEGG pathways in three tissue comparisons 
As shown in Figure 3-11, besides the perturbed pathways (both significantly overrepresented and 
accumulated), a few pathways are only strongly overrepresented (represented by the red dots, with 
high -log10pvalue on x-axis). In Table 3-10 and Figure 3-15, all significant overrepresented pathways 
(without regard to accumulated or not) in three comparisons (DDfat/CTtis, DDtis/DDfat and 
DDtis/CTtis) were listed.  
Two common overrepresented pathways in DDfat/CTtis and DDtis/CTtis are the Hippo network and 
the Cell adhesion molecules (CAM). Seven pathways were significantly overrepresented in both 
DDtis/DDfat and DDtis/CTtis including the 'Focal Adhesion', 'Pathways in Cancer', 'Protein Digestion 
and Absorption' and three myopathies (Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy and 
Arrhythmogenic Right Ventricular Cardiomyopathy).  
Table 3-10 Overrepresented pathways for DEGs in tissue comparisons 
 
Pathway name DDfat/CTtis DDtis/DDfat DDtis/CTtis
Cell adhesion molecules (CAMs) 0.000 0.000
Salivary secretion 0.000 0.003
Staphylococcus aureus infection 0.001 0.015
Hippo signaling pathway 0.001 0.022
Complement and coagulation cascades 0.001
Basal cell carcinoma 0.001
Neuroactive ligand-receptor interaction 0.005 0.004 0.001
Cytokine-cytokine receptor interaction 0.008 0.003 0.000
Asthma 0.012
Pancreatic secretion 0.043
Intestinal immune network for IgA production 0.044
Aldosterone-regulated sodium reabsorption 0.047
Protein digestion and absorption 0.000 0.000
cAMP signaling pathway 0.012
ECM-receptor interaction 0.000 0.000
Hypertrophic cardiomyopathy (HCM) 0.000 0.000
Dilated cardiomyopathy 0.000 0.000
PI3K-Akt signaling pathway 0.004 0.000
Focal adhesion 0.000 0.001
Pathways in cancer 0.002 0.002
Arrhythmogenic right ventricular cardiomyopathy 0.001 0.003
Axon guidance 0.004
cGMP-PKG signaling pathway 0.015 0.007
Regulation of lipolysis in adipocytes 0.003 0.029
Starch and sucrose metabolism 0.047
PPAR signaling pathway 0.012
Morphine addiction 0.010
Rap1 signaling pathway 0.008
GABAergic synapse 0.020
Combined Bonferroni p-value
 Overrepresented pathways (KEGG)
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 Figure 3-15 Summary of overrepresented KEGG pathways in three tissue comparisons  
(A) A clustering of overrepresented pathways in 3 comparisons (DDfat/CTtis, DDtis/DDfat and 
DDtis/CTtis). The intensity of the shading indicates the significance of the pathway overrepresentation. 
All blue boxes have a Bonferroni adjusted p-value of ≤0.05, white boxes have a p-value of >0.05. The –
log10(Bonferroni p-value) was used in the heatmap.  
(B) The Venn diagram depicts the number of overrepresented pathways in three comparisons. 
  
 68 
3.3.5 Pathway overrepresentation analysis using DEGs in DD cells 
3.3.5.1 DEGs in DD cells 
DDcells cultured from DDtis are often used as in vitro cell models to study cellular mechanisms 
involved in DD. To gain an in depth understanding on the gene expression profiling and pathway 
perturbation of DDcells, analysis of DEGs was first conducted in three comparisons DDtis/CTtis, 
DDcell/CTcell and DDtis/DDcell (Figure 3-16A). These filtered DEGs were used for pathway analysis. 
The distribution of gene expression fold change in each comparison is shown in volcano plots in 
Figure 3-16B.  
3.3.5.2 Enrichment of perturbed KEGG pathways in DD cells 
Pathway perturbation analysis combining pathway overrepresentation and pathway accumulation was 
performed using DEGs in DDtis/CTtis, DDcell/CTcell and DDtis/DDcell. In DDtis/DDcell, the most 
significantly perturbed pathway is the 'Cytokine-cytokine receptor interactions pathway' (see Figure 3-
17A), which is likely to be the main molecular difference between DD tissue and cell models. In 
DDcell/CTcell, no candidate pathway was predicted to obtain strong accumulation due to the DEGs 
(see Figure 3-17A).  
The significantly overrepresented pathways among three comparisons (DDtis/CTtis, DDcell/CTcell and 
DDtis/DDcell) were also compared. The Venn diagram in Figure 3-17B illustrates the number of 
common and individual pathways among three comparisons. By comparing the similarities between 
DDcell/CTcell and the DDtis/CTtis, common pathways contributing to DD pathogenesis in both tissue 
and cell models might be identified if the tissue-cell difference is removed (represented by 
DDtis/DDcell). Therefore, as highlighted in the Venn diagram, 5 overrepresented pathways were 
uniquely shared between DDtis/CTtis and DDcell/CTcell, which include the 'Focal Adhesion', three 
myopathies, and 'Straphylococcus aureus Infection' which is related to inflammation66.  
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Figure 3-16 Volcano plots for DEGs in in vitro cell models 
(A) Filters applied on gene expression change under 3 conditions: (a) DDtis vs CTtis; (b) DDcell vs. 
CTcell; (c) DDtis vs DDcell.  
(B) Volcano plots of distribution of DEGs in each comparison, where log2 fold change (x-axis) is plotted 
against −log10 FDRadjusted q-value (y-axis). Significant DEGs are colored in red, while the rest are 
colored in black.  
 
  
 70 
 
 
Figure 3-17 Perturbed pathways in in vitro cell models 
(A) The most significantly perturbed pathways in DDtis vs CTtis, DDcell vs. CTcell and DDtis vs DDcell. 
Bonferroni adjusted p-value ≤ 0.05 was applied to select significantly perturbed pathways.  
(B) The left Venn diagram depicts the overrepresented pathways uniquely shared in DDtis/CTtis and 
DDcell/CTcell. The 5 pathways and their p-values are listed in the right table. 
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3.4 Characterization of alternative splicing (AS) in DD  
3.4.1 Comparison of the AS classes in disease tissues and controls 
To explore the extent of AS between disease and control tissues, we first classified the differential AS 
events for each gene using spliceR46. SpliceR first constructs the hypothetical pre-RNA based on the 
exon information from all transcripts originating from that gene46. Subsequently, all transcripts are 
compared to this hypothetical pre-RNA in a pairwise manner, and AS events are classified and 
annotated46.  
Here, six common types of gene splicing events were considered including the exon skipping/inclusion 
(ESI), intron skipping/inclusion (ISI), alterative 5' splice sites (A5), alternative 3' splice sites (A3), 
multiple exon skipping (MESI) and mutually exclusive exons (MEE)46. In all 3 comparisons 
(DDfat/CTtis, DDtis/DDfat and DDtis/CTtis), different classes of AS vary in relative abundance but 
maintain constant relative ratios among all AS events (Figure 3-18). The most frequent AS class was 
ESI in all comparisons (>30%), followed by A3 and A5 (in total  ~50%), MESI (~10%) and ISI (~9%). 
The most rare AS form was MEE.  
 
Figure 3-18 The classification of AS events in tissue comparisons 
The relative abundance of individual AS event in each tissue comparison: DDfat/CTtis, DDtis/DDfat and 
DDtis/CTtis. Six major splicing events were analyzed including exon skipping /inclusion (ESI), intron 
skipping/inclusion (ISI), alterative 5' splice sites (A5), alternative 3' splice sites (A3), multiple exon 
skipping (MESI) and mutually exclusive exons (MEE). 
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Notably, a large difference in the number of AS events was observed in DDtis compared to DDfat or 
CTtis (Figure 3-18), whereas in DDfat compared to CTtis, only 375 AS events were detected. The 
same holds true for each of the AS event type (ESI, AD, A5, MESI and IR). The high number of 
differential AS events suggests a distinct set of transcripts exist in DD tissue, which may contribute to 
the DD nodule disease phenotype. Moreover, a DD tissue-specific mechanism regulating AS might 
underline the observed AS difference. 
3.4.2 Characterization of isoform switching in DDtis  
To understand the impact of AS on individual isoforms, we focused on isoform switching with in a 
gene in DDtis compared to DDfat or CTtis (described in Method 2.4.6). 
Using spliceR46, a set of 30 high confidence isoform switches, defined by a large change of isoform 
fraction (IF) between two conditions, was identified between tissue comparisons. In DDtis/CTtis, 21 
isoform switches were identified. Similarly, in DDtis/DDfat, 17 isoform switches were identified (Table 
3-11). Between DDtis/CTtis and DDtis/DDfat, common isoform switches were identified, which were 
isoforms for 7 genes including PLOD2, TPM1, SPON2, MYO1D, GOLT1B, FAM198B and ACSL1. In 
DDfat/CTtis, only 4 isoform switches remained after the first four filters, however, by checking junction 
reads on IGV, none of them can be validated. 
The IF value for each of the 30 isoforms in each sample was plotted in a heatmap in Figure 3-19. The 
majority of isoform switches displayed a higher IF in DDtis compared to both DDfat and CTtis. 
Interestingly, in DDfat, a high value of IF for isoforms in some genes (such as CD44, ITGA7 and 
ACTN1) was also observed (in more than 5 out of 9 DDfat samples). However, the IF change (dIF 
value) did not meet the minimal threshold for dIF (Method 2.4.6) if mean IF was compared across 
pooled samples. This suggests isoform switches identified in DDtis may be also present in DDfat, 
although not statistically significant. In sum, we identified isoforms switches in DDtis compared to 
either internal control DDfat or external control CTtis. This suggests these isoforms may have specific 
functions contributing to the development of disease tissues.   
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Table 3-11 Isoform switches in tissue groups 
 
 
 
Group Isoform Name
Ensembl 
Transcript ID
Cufflinks 
Transcript
Cod
e
Start 
Exon
Stop 
Exon
Exon 
No. ESI MESI ISI A5 A3
log2 
Isoform 
dIF
log2 
Isoform 
FC
log2 
Gene 
FC
Gene
ACSL1-201 ENST00000437665 TCONS_00245614 j 2 21 19 2 0 0 1 1 -0.8 -3.9 -3.1 ACSL1
ACTN1-001 ENST00000193403 TCONS_00095839 = 1 21 21 5 1 0 2 3 1.0 1.7 0.8 ACTN1
ATRN-001 ENST00000446916 TCONS_00194582 = 1 25 25 1 0 0 0 0 0.6 1.8 1.1 ATRN
BMP1-010 ENST00000306349 TCONS_00293516 = 1 16 16 2 1 0 0 4 1.2 3.2 1.8 BMP1
CD44-003 ENST00000263398 TCONS_00045757 = 1 9 9 1 1 0 2 3 1.0 2.0 1.1 CD44
COL16A1-001 ENST00000373672 TCONS_00018932 = 2 71 70 6 1 0 5 5 1.0 3.2 2.2 COL16A1
DNAJB11-201 ENST00000265028 TCONS_00221564 = 1 10 10 0 0 0 1 1 0.7 1.1 0.4 DNAJB11
FAM198B-004 ENST00000296530 TCONS_00244905 = 2 5 3 1 0 0 0 0 1.1 2.6 1.4 FAM198B
FBLN2-002 ENST00000295760 TCONS_00213535 = 2 17 16 2 0 2 0 1 1.0 1.8 0.7 FBLN2
FOS-001 ENST00000303562 TCONS_00090589 = 1 4 4 1 0 0 1 1 -0.7 1.5 2.3 FOS
GOLT1B-001 ENST00000229314 TCONS_00064583 = 1 5 4 0 1 0 0 0 0.9 2.2 1.2 GOLT1B
ITGA7-002 ENST00000553804 TCONS_00076251 = 1 25 25 0 1 1 0 1 0.7 -2.2 -2.9 ITGA7
KIF1B-003 ENST00000377093 TCONS_00001027 = 2 21 20 2 0 0 0 1 0.9 1.7 0.8 KIF1B
LEPRE1-001 ENST00000296388 TCONS_00020151 = 1 15 15 1 0 0 2 5 0.7 2.7 2.0 LEPRE1
MYO1D-004* TCONS_00138059 j 2 22 20 3 1 0 0 1 0.7 3.5 3.0 MYO1D
PALMD-001 ENST00000263174 TCONS_00007250 = 1 8 8 0 1 0 2 2 0.6 -1.3 -1.9 PALMD
PLOD2-001* TCONS_00229911 j 2 20 18 2 0 0 1 4 0.6 2.2 1.5 PLOD2
PLXDC1-008 ENST00000444911 TCONS_00138773 = 1 13 13 0 2 0 1 1 0.7 3.1 2.2 PLXDC1
SPON2-002 ENST00000290902 TCONS_00239444 = 2 6 4 1 0 0 2 1 0.8 4.0 3.2 SPON2
SSC5D-005 ENST00000594321 TCONS_00159739 = 1 3 3 0 0 0 0 0 0.6 3.7 2.9 SSC5D
TPM1-028 ENST00000559556 TCONS_00101180 = 1 9 8 3 1 2 3 2 2.0 3.7 1.8 TPM1
ACSL1-201 ENST00000437665 TCONS_00245614 j 2 21 19 2 0 0 1 1 -0.7 -3.6 -2.9 ACSL1
COL1A2-001* TCONS_00280877 j 2 53 52 0 0 0 4 7 -0.6 3.4 3.9 COL1A2
COL3A1-001 ENST00000304636 TCONS_00178764 = 1 51 51 1 0 0 2 1 -1.1 3.9 5.0 COL3A1
FAM198B-004 ENST00000296530 TCONS_00244905 = 2 5 3 1 0 0 0 0 0.6 2.0 1.4 FAM198B
GOLT1B-001 ENST00000229314 TCONS_00064583 = 1 5 4 0 1 0 0 0 1.0 2.2 1.2 GOLT1B
MYO1D-004* TCONS_00138059 j 2 22 20 3 1 0 0 1 0.7 3.6 2.8 MYO1D
PALLD-002* TCONS_00238553 j 3 11 9 1 1 0 0 2 1.1 3.2 2.1 PALLD
PFKFB3-002 ENST00000379775 TCONS_00031452 = 1 15 15 2 0 0 1 2 -0.6 -3.3 -2.6 PFKFB3
PLOD2-001* TCONS_00229911 j 2 20 18 2 0 0 1 4 0.7 2.5 1.8 PLOD2
PYGL-001 ENST00000216392 TCONS_00094963 = 1 20 20 1 0 0 2 1 -0.7 -2.3 -1.6 PYGL
RBPMS-003 ENST00000339877 TCONS_00294164 = 1 7 7 2 1 0 1 0 -0.8 -1.7 -0.8 RBPMS
RCN1-003 ENST00000381132 TCONS_00204262 = 1 4 4 1 0 0 1 1 0.7 2.4 1.8 RCN1
SEC23A-001* TCONS_00094550 j 3 21 19 2 1 0 1 1 0.9 2.3 1.4 SEC23A
SLC39A6-002* ENST00000269187 TCONS_00149029 j 2 10 9 0 0 0 1 0 0.9 2.0 1.1 SLC39A6
SPON2-002 ENST00000290902 TCONS_00239444 = 2 6 4 1 0 0 2 1 0.7 3.7 3.0 SPON2
TPM1-028 ENST00000559556 TCONS_00101180 = 1 9 8 3 1 2 3 2 1.5 3.0 1.5 TPM1
Code j: represents "novel" isoforms not found in Ensembl b75
Code =: represents known isoforms in Ensembl b75
DDtis/CTtis
DDtis/DDfat
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Figure 3-19 A heatmap representation of IF of 30 isoforms in individual tissue groups 
In any of the 3 comparisons (DDtis/DDfat, DDtis/CTtis and DDfat/CTtis), transcripts defined as isoform 
switches were selected. Each box (in row) represents the calculated IF value for a given gene in each 
sample. The Z-score normalized IF of each isoform was used in the heatmap, in which the red color 
indicates the high expression, whereas blue indicates the low expression. Spearman’s rank correlation 
was applied. The symbol * represents isoforms identified as novel isoforms. 
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3.4.3 Altered expression of five splicing factors in DDtis 
An emerging concept proposes that tissue-specific splicing factors can coordinate AS involving 
isoforms encoding proteins to function in biologically coherent pathways and contribute to tissue 
specification103. Therefore, to understand the cause of the observed pattern of isoform usage in DD 
relevant tissues, I analyzed the expression change of 71 known splicing factors104 using Cuffdiff 
results. In total, five splicing factors showed significant gene expression change in DDtis compared to 
CTtis. RBFOX2 (RNA Binding Protein, Fox-1 Homolog 2) and PTBP2 (Polypyrimidine Tract Binding 
Protein 2) were significantly increased in DDtis, whereas NOVA1 (Neuro-Oncological Ventral Antigen 
1), ESRP1 (Epithelial Splicing Regulatory Protein 1) and ESRP2  (Epithelial Splicing Regulatory 
Protein 2) were significantly decreased in DDtis (Figure 3-20A). The expression of these splicing 
factors in individual samples was shown in a heatmap in Figure 3-20B.  
To test whether there is any correlation among the co-expressed splicing factors, Spearman's rank 
correlation test was performed using all 50 tissue samples (DDtis, DDfat and CTtis). As shown by the 
dendrogram (Figure 3-20B), a positive correlation was identified between RBFOX2 and PTBP2 
expression (Spearman ρ=0.61, Bonferroni adjusted p-value < 0.05). Additionally, a strong positive 
correlation was observed between ESRP1 and ESRP2 gene expression (ρ=0.93, Bonferroni adjusted 
p-value < 0.05). In summary, the gene expression of five splicing factors was significantly altered in 
DDtis and it may represent one of the many expression profiles that characterize the intrinsic 
properties of DD tissues and their tissue-specific regulation of AS.  
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Figure 3-20 The significant gene expression change of 5 splicing factors in DDtis/CTtis 
(A) Box plots of 5 splicing factors. Compared to CTtis, RBFOX2 and PTBP2 were significantly increased, 
whereas NOVA1, ESRP1 and ESRP2 were significantly decreased in DDtis. The y-axis is the FPKM of of 
a gene from Cuffdiff result. FDR adjusted q-value was applied. (*q ≤0.05, **q-value≤0.01, ***q-value 
≤0.001). 
(B) A heatmap representation of Z-score normalized expression of five splicing factors in individual tissue 
samples. The distance measure for hierarchy clustering of samples and gene expression was one-minus 
Spearman’s rank correlation. A positive correlation was observed between RBFOX2 and PTBP2 gene 
expression (Spearman’s rank correlation coefficient ρ=0.61, p-value < 0.001). A strong positive 
correlation was also observed between ESRP1 and ESRP2 gene expression (ρ=0.93, p-value < 0.001).   
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3.4.4 Specific correlation patterns between isoform switches and splicing factors in 
DD 
To test whether there is a tissue-specific association between isoform switches and the gene 
expression of splicing factors, I took each isoform exhibited isoform switching (30 isoforms in Figure 3-
19) and calculated the correlation coefficient between the IF of each isoform and the gene expression 
of each of the 5 splicing factors in each tissue type (DDtis, DDfat and CTtis). Spearman’s rank 
correlation coefficient was used to assess the association and Bonferroni adjustment was applied.  
In DDtis, positive correlations between RBFOX2 expression and IF of two isoforms were observed 
(Figure3-21A). RBFOX2 expression was strongly associated with the IF of PLOD2-001* (Spearman’s 
rank correlation coefficient ρ= 0.92, Bonferroni adjusted p-value < 0.05) in DDtis, in contrast to no 
correlation in DDfat and CTtis. Similarly, a gain-of correlation was observed between RBFOX2 
expression and IF of SPON2-002 (ρ= 0.72, Bonferroni adjusted p-value < 0.05) in DDtis.  
In DDtis compared to both DDfat and CTtis, RBFOX2 was significantly increased as shown in Figure 
3-20A. This suggests increased RBFOX2 expression may be causal for the increased isoform usage 
of PLOD2-001* and SPON2-002. RBFOX was known to regulate AS of PLOD2 (procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 2)105, which encodes a regulator of collagen stiffness106. Enhanced 
inclusion of the last exon of PLOD2 by RBFOX2 can lead to elevated expression of PLOD2-001, 
which is associated with TGF β-induced fibrosis106,107. However the PLOD2-001* is a 'novel' isoform 
which is not in the Ensembl transcript database, though it is only different from PLOD2-001 in A3 and 
A5 sites. Therefore, the presence of PLOD2-001* isoform needs to validated and the regulatory 
association between PLOD2-001* and RBFOX2 needs to be tested in vitro.  
In contrary to RBFOX2, ESRP1/2 expression was significantly decreased in DDtis compared to 
healthy control CTtis. In CTtis, ESRP1/2 expression was negatively correlated with CD44-003 (ρ = -
0.95, -0.93 separately, p-values < 0.05). However this correlation was lost in DDtis as well as in DDfat 
(Figure3-21B). CD44 isoform switching represents a very conserved splicing event regulated by 
ESRP1/2 in EMT and malignant cancer progression49, which is used as an example for reduced AS 
usage in DDtis in the next session.  
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Figure 3-21 The tissue specific correlation between gene expression of splicing factors and IF of 
isoforms 
The Spearman’s rank correlation coefficient ρ for gene expression of 5 splicing factors and IF of 30 
candidate isoforms in each tissue type were calculated. Bonferroni adjusted p-value ≤ 0.05 was applied. 
In total, significant correlation was identified in 4 pairs, including 2 isoforms (PLOD2-001* and SPON2-
002) correlated with RBFOX2 (A). and one isoform CD44-003 correlated with ESRP1 and ESRP2. 
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3.4.5 Examples of tissue-specific AS in DDtis 
 3.4.5.1 Example 1: reduced CD44 AS usage in DDtis and DDfat 
As illustrated in Figure 3-22A, human CD44 has 19 expressed exons, of which 10 exons are 
constitutive exons (C1-C10), whereas 9 exons are variant exons (V2-V9). The standard isoform 
CD44s, is composed of constitutive exons C1-C5 at the 5' end and C6-C10 at the 3' end. Between 
exon C5 and C6, there are nine variable exons (V2-V10) which are alternatively spliced to produce a 
plethora of isoforms108. CD44s and CD44v protein isoforms are all transmembrane proteins that 
function primarily to maintain tissue structure by mediating cell–cell and cell–matrix adhesion109 
(Figure 3-22B). Inclusion of the variable exons lengthens the extracellular membrane-proximal region 
by forming a heavily glycosylated stalk-like structure that provides interaction sites for additional 
molecules. 
Here, the CD44 AS events in DDtis were first visualized in Sashimi plot (Figure 3-22C). In both DDtis 
(n=9, out of 10) and DDfat (n=9), reduced junctions between exon C5 and exon C6 were observed 
suggesting less use of CD44 variant exons compared to CTtis. Moreover, increased expression of the 
standard isoform CD44s was detected in DDtis compared to either DDfat or CTtis (Figure 3-22D). The 
gene expression of CD44, which represents the sum of all CD44 isoforms, was also increased in 
DDtis compared to either DDfat or CTtis (Figure 3-22E). This suggests CD44s is the dominant isoform 
in DDtis, which contributes to the most of CD44 expression observed in DDtis. In addition, in both 
DDtis and DDfat, a loss of correlation between ESRP1/2 and CD44s isoform fraction was observed 
(Figure 3-21B).  
Taken together, the reduced CD44 AS and its loss-of-correlation by ESRP1/2 were not only observed 
in DDtis but also in DDfat, suggesting the altered CD44 AS and ESRP1/2 expression may modulate 
both disease tissue (DDtis) and its niche (DDfat). 
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Figure 3-22 The significant increased IF of CD44s and CD44 gene expression in DDtis  
(A) CD44 gene structure consists of 10 constitutive exons (C1-C10) and 9 variant exons (V2-V10) in 
human, The standard isoform CD44s is transcribed from constitutive exons only (C1-C10). 
(B) The CD44s isoform has basic transmembrane domains, whereas CD44v has additional longer stems, 
which contains the variant exon(s). The figure was adapted from atlasgeneticsoncology.org/-
Genes/CD44ID980CH11p13.html. 
(C) Loss of alterative spliced CD44 isoforms in DDtis and DDfat compared to CTtis. 
(D) CD44s isoform expression, and (E) CD44 gene expression were increased in DDtis compared to 
both DDfat and CTtis. FDR-adjusted p-value was calculated (***p-value ≤0.001).   
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3.4.5.2 Example 2: an imbalance of FBLN2 isoform ratio in DDtis 
Another interesting candidate is an isoform of Fibulin-2 (FBLN2). FBLN2 gene contains 18 exons and 
encodes an ECM glycoprotein110 (Figure 3-23A). The exon 9 can be alternative spliced and exclusion 
of exon 9 leads to a short protein isoform FBLN2-002, which is also named as FBLN2-Δexon9110.  
In line with the increased IF of FBLN2-Δexon9 detected by splice R (Figure 3-19), reduced expression 
of exon 9 was observed on Sashimi plot in 50% DDtis compared to DDfat or CTtis (Figure 3-23B). The 
overall FBLN2-Δexon9 isoform expression was clearly increased in DDtis compared to either DDfat or 
CTtis (Figure 3-23C, FDR q-value < 0.01), but the overall gene expression was not changed, leading 
to increased IF of FBLN2-Δexon9 in DDtis, suggesting a differential regulation of FBLN2-Δexon9 
compared to other FBLN2 isoforms.  
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Figure 3-23 The significantly increased isoform fraction of FBLN2-Δexon9 in DDtis  
A) The gene structure of FBLN2. Figure was adapted from Timl et. al 110. 
(B) The exon 9 of FBLN2 in DDtis has reduced coverage corresponding to reduced expression. 
Increased Exon 9 skipping was observed in DDtis, as indicated by the higher number above the junction 
spanning exon9. 
 (C) Significantly increased isoform fraction of FBLN2-Δexon9 was detected in DDtis and DDfat 
compared to CTtis (FDR adjusted q-value <0.01). However the gene expression of FBLN2 was not 
significantly increased. 
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3.4.5.3 Example 3: Increased COL1A2 AS usage as a feature in DDtis 
As observed in Figure 3-19, a few isoforms displayed a lower IF in DDtis compared to either DDfat or 
CTtis, including two collagen isoforms (COL1A2-001* and COL3A1-001). However the expression of 
both isoforms and their gene expression were significantly increased in DDtis compared to two 
controls. Therefore, the likely explanation is that the number of isoforms in DDtis is increased.  
As shown in Figure 3-24, Sashimi plot was used to visualize all the isoforms in COL1A2 in DDtis. 
Increased number of reads were mapped across exon-exon junctions in 9 DDtis compared to DDfat 
and CTtis suggesting increased AS of COL1A2. Therefore, although the isoform expression of 
COL1A2-001* was increased in DDtis, its contribution to COL1A2 gene expression (measured by IF in 
Figure 3-19) was reduced due to a larger number of alternatively spliced COL1A2 isoforms. This 
indicates a specific set of COL1A2 isoforms were produced in most of DDtis, which might be a general 
feature of DD affected tissues.  
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Figure 3-24 The increased use of AS of COL1A2 in DDtis  
Increased alterative spliced COL1A2 isoforms in 9 out of 10 DDtis compared to a representative sample 
for both DDfat and CTtis. 
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3.4.5.4 Example 4:  Extensive COL3A1 AS usage as a subgroup feature of DDtis  
In accordance to COL1A2, increased use of AS of COL3A1 was also observed in the majority of DDtis 
(70%, shown in Figure 3-25), compared to both DDfat and CTtis. However, a remarkable variance 
within DDtis samples was noted. Extensive AS usage indicated by a large number of splicing junctions 
was observed in 4 DDtis samples (DDtis 1, 6, 7 and 5), which were referred as DD subgroup 1. In 
DDtis 3, COL3A1 also exhibited elevated AS but to a lesser extent compared to DDtis samples in DD 
subgroup 1.  
This variance with in DDtis was also observed in RBFOX2 expression (Figure 3-20B). RBFOX2 
expression was about 2-fold higher in DD subgroup 1 compared to the rest of DDtis (Welch's t-test 
p=0.01). However, RBFOX2 expression was not correlated with COL3A1-001 IF (Spearman's rank 
correlation test, p-value > 0.05). So it is likely the COL3A1 AS is regulated by other regulatory 
mechanisms instead of by RBFOX2. 
Collectively, a larger number of COL3A1 isoforms was observed in the majority of DDtis compared to 
either DDfat or CTtis. Particularly, a massive increase in COL3A1 AS was observed in a subset of 
DDtis (4 samples in DD subgroup 1), which might represent a differential clinical profile of the patients 
or molecular mechanism of pathogenesis. 
 
 86 
 
Figure 3-25 Extensive AS of COL3A1 in a subset of DDtis 
Increased use of AS for COL3A1 in 6 out of 10 DD tissues compared to a representative DDfat was 
observed in the Sashimi plot. A circle above an arc indicates the number of reads that span an exon–
exon junction (minimal number of 40 mapped reads). The blue transcript at the bottom represents the 
longest transcript of COL3A1 in Refseq.  
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3.4.6 Characterization of two subgroups in DD based on COL3A1 and gene expression 
profiling 
DD is considered as a progressive fibromatosis disease that may be heterogeneous in many aspects 
including the severity and clinical appearance111, treatment effect and recurrence rates (27% to 
66%)112. These may arise from differential mechanisms of pathogenesis. Identification of biomarkers, 
which show homogeneity within one subgroup but difference in other subgroups, may help identifying 
subgroups of patients and reveal pathophysiological insights. 
DDtis samples can be divided into two subgroups based on substantial or limited AS of COL3A1, as 
shown in Figure 3-25. To quantify the difference of the effect on gene level, the total expression of all 
isoforms, which means COL3A1 gene expression, was examined. In DD subgroup 1 (DDtis 1, 6, 7 and 
5) with extensive AS, expression of COL3A1 was more than 10-fold higher than DD subgroup 2 
(10960 FPKM vs. 925 FPKM) (Figure 3-26A).  
The same classification of these two subgroups was determined using unsupervised hierarchical 
clustering of gene expression profiling, as previously showed in Figure 3-9A, suggesting a consistent 
molecular difference between subgroup 1 and 2. To capture the fundamental differences between two 
subgroups, I used Cuffdiff results to identify differentially expressed genes (DEGs) between two 
subgroups (defined as 1.5 fold change of gene expression, FDR adjusted q-value ≤ 0.05) (Figure 3-
26A).  
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Figure 3-26 The stratification of two subgroups of DD patients  
(A) COL3A1 expression was significantly increased in DD subgroup 1 compared to subgroup 2. 
Subgroup 1 was referred to 4 DDtis samples exhibited extensive COL3A1 AS 
(B) Gene expression profiles in DD subgroup 1, DD subgroup 2 and DDfat. 
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Then GO terms and pathway overrepresentation analysis using significant DEGs (478 genes) were 
conduced using Enrichr tool65. As shown in Table 3-12, the most significant overrepresented GO 
terms were the 'ECM organization', 'ECM structure organization and disassembly' and 'collagen fibril 
organization'. The majority of these genes exhibited higher expression in DD subgroup 1 compared to 
subgroup 2, suggesting increased ECM accumulation and enhanced ECM stiffness in DDtis samples 
in subgroup 1.  
Using Enrichr KEGG pathway analysis66, four pathways were overrepresented (Table 3-13) including 
'ECM-receptor interactions' (12 DEGs) and 'PI3-Akt Signaling pathway' (22DEGs). The 24 DEGs 
overlapped with 'Pathways in Cancer' include genes encoding protein in the TGFβ pathway (TGFβ2, 
TGFβ3 and LAMB1), Wnt pathway (WNT11, LEF1 and FZD4), transcription factors (CEBPA and 
RUNX1), cytokines (CDKN1 and CDKN2A), and fibroblast growth factors (FGF2 and FGF16). The 
'Protein Digestion and Abortion' pathway was only considered as associated but not functional in 
DDtis since all the 13 overlapped DEGs with this pathway are genes encoding ECM.  
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Table 3-12 Overrepresented GO biological processes in DD subgroup 1/subgroup 2 
 
 
Table 3-13 Overrepresented pathways in DD subgroup 1/subgroup 2 
  
GO  Biological Process Adjusted p-value Z-score
Combined 
score
1 extracellular matrix organization 1.0E-13 -2.4 71.2
2 extracellular structure organization 1.0E-13 -2.4 71.2
3 extracellular matrix disassembly 6.2E-09 -2.2 41.3
4 collagen fibril organization 5.2E-07 -2.5 36.6
5 multicellular organismal metabolic process 1.8E-06 -2.2 28.6
6 collagen metabolic process 2.0E-06 -2.2 28.4
7 multicellular organismal macromolecule metabolic process 4.1E-06 -2.2 27.1
8 collagen catabolic process 1.7E-05 -2.2 23.6
9 response to wounding 9.1E-05 -2.4 22.0
10 multicellular organismal catabolic process 3.6E-05 -2.2 22.0
KEGG pathway 2016 Overlap Adjusted p-value Z-score Combined score
Protein digestion and absorption 13 0.000 -1.72 14
ECM-receptor interactions 12 0.000 -1.68 14
Pathways in cancer 24 0.004 -2.03 11
PI3K-Akt signaling pathway 22 0.004 -2.02 11
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3.5 Integrative analysis combining exome and RNA-seq data 
3.5.1 The overlapping cohort for WES and RNA-seq design 
The 11 patients in RNA-seq cohort were also included in the WES study. RNA-seq on a larger sample 
size, for example RNA-seq for DDtis from the rest of 39 patients in WES study, was not conducted 
mainly owing to our stringent case-control sample collection criteria, such as a) matched age between 
case and control when samples were collected, b) the availability and the high quality of RNA from 
tissue samples and cells. Although the cohorts for RNA-seq and WES studies do not completely 
match, a comparison of both studies may provide insight to the true candidate genes and pathways.  
3.5.2 Functional candidate genes with genetic predisposition  
In the whole exome study, 12 genes carrying rare variants were identified as DD phenotype-related 
genes. To assess whether these genes have transcriptomic consequences, I examined the gene 
expression of these 12 genes in the RNA-seq gene expression data. As shown in Table 3-14, 8 of the 
12 candidate genes displayed significantly differential expression in at least one comparison group in 
tissue comparison (DDfat/CTtis, DDtis/DDfat and DDtis/CTtis) or cell comparison (DDcell/CTcell). The 
expression of 6 genes was significantly changed in more than two comparisons, suggesting functional 
roles of these genes in transcriptome. They are genes encoding collagen (COL7A1, COL11A1, 
COL5A1 and COL1A2), ROR2 (receptor tyrosine kinase-like orphan receptor 2  — a single-span 
transmembrane receptor regulating both canonical113,114 and noncanonical Wnt signaling 
pathway115,116), and FLNB (Filamin B). Besides increased gene expression, increased AS usage for 
COL1A2 was also identified in DDtis (Figure 3-24), suggesting COL1A2 as a functional candidate for 
DD.  
In summary, combining exome and RNA-seq data, 6 candidate genes carrying rare variants were 
suggested to play a functional role in DD transcriptome. These candidate genes are COL7A1, 
COL11A1, COL5A1, COL1A2, ROR2 and FLNB. 
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Table 3-14 Functional candidate genes with genetic predisposition   
 
  
Allternative	
splicing
Ch
r EvoTol
Phenolyze
r  (0.0001 -
5.7)
Gene 
burde
n
dbSNP138 Start End Ref Alt Allele count Gene
DDfat
/CTtis
DDtis
/DDfa
t
DDtis
/CTtis
DDcell/
CTcell
9 9.28% 1.2 3 rs35852786 94487187 94487187 C T 3 ROR2 up up up
. 48608296 48608296 G A 1
rs139434755 48629340 48629340 G A 1
rs35623035 48630252 48630252 G A 2
rs139064549 103354135 103354135 G C 2
rs141978499 103544374 103544374 C G 1
. 94055143 94055143 G A 1
. 94057101 94057101 A C 1
rs41306397 137591755 137591755 C T 1
rs199735010 137694750 137694750 C T 1
rs368305377 137702117 137702117 C T 1
rs61739195 137708884 137708884 C T 1
. 58141747 58141747 T C 1
rs116826041 58145348 58145348 T C 1
rs149638325 58148895 58148895 C T 1
rs114260147 149359938 149359938 C G 1
rs104893915 149359991 149359991 C T 1
rs373336251 55240795 55240795 G A 1
rs201830126 55268023 55268023 G A 1
rs61756429 111608216 111608216 T A 1
rs115287852 111612783 111612783 T C 1
rs1801166 112175240 112175240 G C 1
rs141010008 112178781 112178781 C T 1
5 21.06% 1.2 2 rs17223632 141993631 141993631 C T 2 FGF1
. 37879585 37879585 A C 1
rs55943169 37884176 37884176 C A 1
17 15.02% 1.4 2
5 0.24% 1.2 2
ERBB2
APC
down
11 20.26% 1.4 2
7 10.76% 1.4 2
PPP2R1B
EGFR
down down down
up
3 0.04% 1.4 3
5 5.58% 3.6 2
FLNB
SLC26A2
COL7A1
7 0.27% 1.2 2 increase
9 3.48% 1.0 4
COL1A2 up up
up upCOL5A1
Gene annotation
Exome data RNAseq data
Rare variant annotation RNAseq Gene expression
1 0.32% 1.2 3
3 0.86% 1.3 4
COL11A1 up up up
up up up
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3.5.3 Shared overrepresented pathways in the exome and transcriptome data 
To further define the pathogenic contribution of the genetic-relevant pathways identified in the exome 
study, I compared the overrepresented pathways in the exome and transcriptome analysis. The 
common pathways were shown in Figure 3-27 with Bonferroni adjusted p-value (-log10 transformed) 
plotted (The blue boxes represent the significant pathway overrepresentation). 
Among the overlapped 5 pathways, the KEGG Hippo network was overrepresented in exome analysis 
(using 12 candidate genes) and transcriptome analysis of DD/DDfat and DDtis/CTtis. This suggests 
the genetic perturbation of this pathway might have a high penetrance leading to disturbed activity of 
this pathway in the development of disease tissue and its niche. 
Pathways specifically related to DDtis were also identified, which include the 'Focal Adhesion' and 
'PI3-Akt pathway'. Similarly, the 'Pathways in Cancer' was also associated with DDtis, which might 
suggest some common features shared by tumor and the localized benign tumor of DD (DD nodule 
tissue). However this pathway designated by KEGG involves more than ten pathways including the 
'Wnt signaling pathway', 'PI3K-Akt pathway' and 'ECM-receptor interactions' etc 
(http://www.kegg.jp/keggbin/highlight_pathway?scale=1.0&map=map05200&keyword=pathways%20i
n%20cancer). Therefore, the 'Pathways in Cancer' cannot be attributed as a specific functional 
candidate pathway in DD. In addition, genes overlapped with the 'Protein Digestion and Absorption 
pathway' are all ECM genes, which suggest this pathway is only relevant instead of functional.  
In sum, three pathways were suggested to be genetically and functionally overrepresented in DD, 
including the 'Hippo network' contributing to the niche environment, the 'Focal Adhesion' and the 'PI3-
Akt pathway' contributing to the DD phenotype development.  
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Figure 3-27 Overrepresented pathways shared in exome and transcriptome data 
A summary of common pathways overrepresented by exome candidate genes (12 genes) and DEGs in 
transcriptome data from 5 comparisons is shown. The DD subgroup feature represents the pathways 
enriched using DEGs between DD subgroup1 and DD subgroup 2. The intensity of the shading indicates 
the significance of the KEGG pathway overrepresentation using Enrichr analysis. All blue boxes have a 
Bonferroni p-value of <0.05, white boxes have a p-value of >0.05. The negative log10(Bonferroni p-
value) was used in the heatmap.  
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Chapter 4 Discussion   
DD is an aging-related common disease with a high degree of genetic predisposition. Identifying 
genetic components contributing to the disease etiology could greatly improve the pre-symptomatic 
diagnosis and treatment of the disease. Therefore, in this study, I designed three sets of experiments 
to identify genetic components in DD including: 
1) identification of functional variants contributing to a strong GWAS association signal using targeted 
NGS 
2) prioritization of DD phenotype-related genes carrying a mutational burden as revealed by whole 
exome sequencing (WES)  
3) characterization of the transcriptional deregulation in disease tissues/cells using RNA-seq.  
4.1 A candidate gene carries functional variants at the 7p14.1 GWAS locus 
In this study, we applied a 'risk haplotype block' strategy in which the risk allele of the top GWAS 
association lead (ranked by lowest p-value) haplotype block at 7p14.1 was determined by 
interrogating the tagging SNP rs16879765. Using targeted NGS in a discovery cohort (n=96) selected 
according to the 'risk haplotype block' information, we identified a rare deleterious coding variant, 
rs149095633 (C>T, p.P121L), and a common regulatory variant, rs2044831, both situated in EPDR1 
at 7p14.1. 
In the subsequent randomly selected, independent validation cohort, the rs149095633 minor allele T 
was 35-fold enriched compared to large European control populations, suggesting an association 
between the rare allele of rs149095633 and DD.  
The SNV rs149095633 (C>T) leads to an amino acid substitution from proline (CCC) to leucine (CTC) 
at position 121 (p.P121L) in the β-turn domain of EPDR1. Proline is a unique amino acid where the 
side chain is cyclized onto the backbone twice, forming a five-membered ring81. This unique feature 
makes proline unable to occupy many of the main-chain conformations which are easily adopted by all 
other amino acids81. Instead, proline is statistically preferred in β-turns because its cyclic structure is 
ideally suited for the tight β-turns, making it so-called β-proline117. Despite being aliphatic and 
preferred for β-turn structures, prolines are also found on the protein surface117. In contrast, leucine 
prefers to be buried in protein hydrophobic cores and it plays an important role in stabilizing α-
helices81. Therefore, it is likely that this P121L substitution disturbs the local β-turn structure, which 
might lead to a change of EPDR1 function or its intermolecular interactions.  
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Moreover, allele specific expression (ASE) analysis in DD cells suggests that the risk allele T of 
rs149095633 might lead to an increased expression of EPDR1. A higher expression of the DD risk 
allele C of rs2044831 was also observed in DD cells suggesting rs2044831 to be an eQTL for EPDR1. 
Notably, both variants were identified in the EPDR1 gene and related to EPDR1 expression, 
suggesting that EPDR1 is the right candidate gene at the risk locus 7p14.1 associated with DD. 
EPDR1 encodes Ependymin Related 1 Protein. An ortholog of EPDR1 was first identified in reticular 
shaped fibroblasts in brain extracellular fluid in zebrafish and reported to play a role in cell 
adhesion118. The DNA and protein sequence of EPDR1 is highly conserved among vertebrates119. Yet 
the precise function of human EPDR1 is unknown. Higher expression of EPDR1 was observed in 
colon cancer a long time ago hence EPDR1 is also known as UCC1 (Upregulated In Colorectal 
Cancer Gene 1)120. The high expression of EPDR1 was particularly linked to the stemness phenotype 
of colon cancer121 and high-risk myeloma122.  
A recent in vitro knockdown study revealed that decreased EPDR1 expression is associated to 
decreased cellular contractility of DD cells123. This suggests EPDR1 is involved in cell-matrix 
interactions in DD cells and expression of EPDR1 might regulate cellular contractility. Thus, abnormal 
EPDR1 overexpression is likely to increase the cellular contractile activity, which is a hallmark of DD 
cells. If EPDR1 indeed contributes to both cancer and DD etiology, a different or weaker effect of 
EPDR1 is expected in DD, as DD is defined as an aging related benign disease. In our data, the 
changes in ASE of both genetic variants (rs149095633 and rs2044831) observed in vitro may 
translate approximately into an increase of total EPDR1 expression of 1.1-fold in DD cells. Given that 
a 3 fold change in EPDR1 expression was sufficient to affect the contractile phenotype in vitro123, our 
data supports the notion that a modest life-long increase of EPDR1 expression may represent the 
molecular basis of an increased risk to develop DD. In vitro functional studies of the effect on EPDR1 
expression of both variants are to corroborate this hypothesis.  
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4.2 Functional candidate genes contributing to the DD phenotype 
Over the past few years, advances in NGS and its affordable pricing have accelerated genomic 
studies in complex diseases to systematically investigate genetic variants and involved genes using 
WES. RNA-seq data are helpful to reasonably interpret the functional elements of the genome and 
reveal the molecular mechanisms. Here we analyzed whole exomes of 50 DD patients using WES and 
whole transcriptomes in 11 of these patients using RNA-seq.  
Using a phenotype-driven strategy, 12 genes with rare variants were identified as DD phenotype-
related candidate genes. By EvolTol prediction, mutations in these genes are likely to be pathogenic in 
the palmar part of the hand. By incorporating RNA-seq data, 6 of the 12 candidate genes exhibited 
significant differential expression in more than two comparisons involving disease relevant 
tissues/cells (Table 3-14).  
Three genes exhibited a signature related to DDtis or DDcell, of which COL1A2 and COL5A1 showed 
increased expression in DDtis compared to either its matched DDfat or external control CTtis. A 
further gene, FLNB, displayed decreased expression in DDtis and DDcell compared to CTtis and 
CTcell, respectively. Another three genes (ROR2, COL7A1 and COL11A1) exhibited an upregulation 
in a pattern DDtis >DDfat >CTtis. This suggests not only a change of gene expression in the disease 
tissue (DDtis) but also in the niche of the disease tissue (DDfat) compared to healthy CTtis.  
Among the investigated four collagen genes, three (COL1A2, COL5A1 and COL11A1) encode fibril-
forming collagens (type I, V and XI), which function as the principal source of tensile strength in 
tissues124. COL7A1 encodes type VII collagen, the major component of the anchoring fibrils beneath 
the basal lamina which functions as an important adhesion molecule at the dermal-epidermal 
junction125. Overexpression of these collagen genes has been linked to various TGFβ-mediated 
fibrosis conditions126-131.  
Additionally, the altered expression of the other two genes, FLNB and ROR2, was also associated to 
tissue fibrosis. FLNB is an actin-binding protein, which regulates cytoskeleton-dependent cell 
proliferation, differentiation and migration132. A recent study has linked the absence of FLNB to 
increased activity of TGFβ signaling both in vitro and in vivo133. ROR2, a transmembrane protein134 
has been identified as an upregulated cell surface marker for human mesenchymal progenitor cells 
and it is suggested to play a role in cell proliferation and migration135.  Moreover, ROR2 
overexpression was also identified to result in a partially activated state for the Wnt/β-catenin signaling 
and an enhancement of downstream target genes following Wnt3a stimulation in renal cell carcinoma 
cells and HEK293T cells136. Therefore, in the DDfat/CTtis comparison, the increased expression of 
both ROR2 and 6 other genes, which are acting upstream of the Wnt/β-catenin signaling pathway136 
(shown in Figure 3-12A, described in session 3.3.4.1), suggests that the niche of disease tissue 
(DDfat) harbors a partially activated state of the canonical Wnt signaling pathway, which might be 
necessary for TGFβ-mediated fibrosis137 in DDtis. 
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Overall, two clusters of DD candidate genes seem to be related to either disease tissue or its niche. 
Deleterious variants in these genes are likely to affect their functions and to contribute to fibrosis in the 
palm.  
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4.3 The mechanisms involved in DD pathogenesis  
With the goal of finding genetic causes, linkage analysis in a pedigree138 and GWAS studies in DD 
cases and controls19,20 have been performed. As a result, we begin to better understand the genetic 
basis of DD. However, the contributions to DD of particular genetic variants and functional candidate 
genes are still elusive, which might be due to genetic heterogeneity. By GWAS analysis, six DD-
associated loci were identified which harbor genes involved in the Wnt pathway, suggesting that 
genetic variants of these genes belonging to this common pathway are responsible for DD. Recently, 
the development of RNA-seq transcriptome analysis provides an effective way to link genes and their 
products into functional pathways. Therefore, integrating the pathways overrepresented by genes 
carrying genetic variants with pathways affected in transcriptome analysis may help to identify the key 
mechanisms contributing to DD.  
In exome and transcriptome analyses, three common pathways (Hippo network, PI3K-Akt pathway 
and Focal Adhesion) were overrepresented (Figure 3-27), which supports the hypothesis that the 
genetic variants in critical functional pathways may affect pathogenesis in this disease.  
4.3.1 The Hippo network and the altered niche 
The role of adipose tissue around DD tissue had been largely ignored for a long time. In our DD study 
cohort, we constantly observed DD patients having a lean phenotype. This association was also 
independently observed in an epidemiology study of DD in an Icelandic population97, which supports a 
significant low adiposity association with male DD patients. Therefore, it is important to include the 
matched unaffected adipose tissue from DD patients (DDfat) and characterize the possible changes in 
gene expression and function.   
By comparing DDfat with healthy adipose tissue (CTtis), the KEGG Hippo network was suggested to 
be the most significantly perturbed pathway (Figure 3-12B). It represents a 'parent' network including 
the 'child' Hippo signaling pathway (also named as the YAP/TAZ pathway), the Wnt/ß-catenin 
signaling pathway and TGFß pathway (shown in Figure 3-12B). 
By perturbation analysis, YAP/TAZ and Mst1/2, the major effectors of the Hippo signaling pathway139, 
were predicted as accumulated and permanently activated. Recent studies have shown that YAP/TAZ 
can serve as important mechanosensors140 between cells and their microenvironment. 
Under in vivo conditions, cells are exposed to a signaling microenvironment including specific ECM, 
secreted proteins, growth factors and ions, resulting in a soft, topographically featured substrate. This 
microenvironment does not only control the biochemistry of the substrate, but also maintain the 
mechanical properties generated by the substrate. By definition, the mechanical properties indicate 
the elastic or inelastic behavior of a substrate under force, such as the stiffness (resistance to 
deformation), elongation and tensile strength141. The mechanical properties are critical for tissue 
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morphology and function but vary, depending on tissue types. For instance, adipose tissue has a 
stiffness of 2 kPasal (kPa)142 and muscles have more than 12 kPa143. During fibrosis, the tissue 
stiffness is highly increased. For example, during bleomycin-related lung injuries, the localized 
stiffness was increased 5-fold (from 3kPa to 15kPa)144.  
In the DD exome study, genetic rare variants were identified in two collagen genes (COL7A1, a 
anchoring fibril collagen gene and COL11A1, a fibril-forming collagen124 gene), which form fibril 
structures that increase ECM stiffness. In the following whole-transcriptome gene expression profiling 
studies, the expression of both genes was increased not only in DDtis/CTtis, but also in DDfat/CTtis 
comparisons (Table 3-12). This suggests that the tissue stiffness of both disease tissue (DDtis) and its 
niche (DDfat) is increased compared to healthy adipose tissue (CTtis). Recently, a significant 
correlation between increased adipose tissue stiffness and lower BMI was observed145. Taken 
together, we propose a first hypothesis according to which the stiffness of DD palmar fasia (DDfat) is 
likely to increase due to loss of subcutaneous fat (low BMI as a marker). 
Multiple studies have revealed that the increased stiffness of substrate can inhibit the Hippo signaling 
pathway and induce YAP/TAZ activity146.  Furthermore, the stiffness of substrate has been recently 
reported to promote adipocyte progenitors (with low cellular stiffness) to differentiate into fibroblasts 
(higher cellular stiffness), which positively feedback to further increase tissue stiffness147. This leads to 
a second hypothesis, which suggests an extensive source of fibroblasts in the early stage of DD.  
As RNA-seq only captures the transcriptome at a given time point, it is difficult to interpret whether the 
inactivation of the Hippo pathway and an increased YAP/TAZ activity is causal or a functional 
consequence. However, in the exome study, the KEGG Hippo network was one of the 
overrepresented pathways based on 12 candidate genes. This suggests a third hypothesis, according 
to which the genetic predisposition in the Hippo network component may lead to the altered YAP/TAZ 
activity in the niche adjacent to DD.   
Overall, in DDfat (the palmar adipose tissue surrounding DDtis), the Hippo pathway is suggested to be 
inactive, which leads to activation of YAP/TAZ effectors. Moreover, the increased expression of fibrillar 
collagen genes in DDfat may increase tissue stiffness, which further activate the YAP/TAZ pathway 
and might lead to adipocyte-fibroblast transition. In addition, a genetic burden on the Hippo network or 
collagen genes may enhance the activity of the YAP/TAZ pathway. 
4.3.2 Fibrosis signatures of DD 
The activation of YAP/TAZ is known to promote TGFβ production148,149. In the gene expression 
profiling analysis, TGFβ expression was highly increased in DDtis compared to DDfat or CTtis, which 
is in accordance with previous findings. TGFβ release induces fibroblast proliferation and 
myofibroblast transition12. Transition to myofibroblasts is characterized by α-SMA expression, high 
contractile activity and enhanced ECM deposition14. The extensive deposition of ECM increases the 
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tissue stiffness, which further amplifies the activity of the TGFβ pathway and eventually leads to 
fibrosis141.  
In this study, several signatures related to DD tissues were characterized including prominent ECM-
receptor interactions and fibrosis tissue-specific splicing. The enhanced ECM-receptor interactions are 
general features of fibrosis and have been associated with DD in other expression profiling studies33. 
However, we here provided for the first time a basic understanding of fibrosis-specific splicing 
signatures in DDtis.  
Alternative splicing (AS) is often regulated in a tissue-specific manner103. As a result, a gene 
undergoing AS can encode distinct protein isoforms involved in different biological processes in 
specific tissues150. The changes in AS have been linked to translation of aberrant proteins that can 
contribute to many diseases, such as Alzheimer's disease151,152, Parkinson's disease153, cystic 
fibrosis154 and cancer155,156. The effect of AS in DD has not yet been addressed. Therefore, taking 
advantage of RNA-seq's potential to detect AS, I adopted an isoform-fraction (IF) guided strategy to 
identify changes of AS in DDtis. 
First, DDtis displayed the highest use of AS compared to its matched internal control DDfat and CTtis. 
As a result, we found most of the genes to show AS, generating a large amount of differentially 
expressed isoforms between DDtis and two control tissue (DDfat or CTtis) in the Cuffdiff result.  
Second, a small set of 30 isoforms displayed isoform-switching events in DDtis (compared to either 
DDfat or CTtis), suggesting potential differential functions of the isoforms from the same gene or an 
altered regulation mechanism of AS. Genes exhibiting isoform switching in DDtis were found to be 
associated with fibrosis progression, such as acquired mesenchymal features (CD44v to CD44s157), 
cellular abnormalities (Increased isoform ratio of FBLN2-Δexon9158,159), and contraction and 
organization of stress fibers (increased TPM1-028160). 
Third, among all collagen genes, only COL1A2 and COL3A1 displayed extensive increase in the 
number of isoforms, the majority of which were generated by exon-skipping events. Both COL1A2 and 
COL3A1 are fibrillar proteins161, which provide tensile strength and stiffness to the ECM161. Distinct 
COL1A2/COL3A1 isoforms may lead to expression of protein isoforms with different structural and 
functional properties. Recently, AS of COL1A2 was associated with the malignancy of colon cancer 
progression162, in which ECM stiffness clearly plays a causative role to tumor formation and 
progression. Therefore, it is likely that increased AS and expression of the fibrillar collagen genes, 
COL1A2 and COL3A1 can contribute to the enhanced ECM stiffness and cellular growth in DDtis.   
Thus, the observed fibrosis tissue specific AS may not only represent a consequence of 
cellular/extracellular abnormalities in DDtis, but also underline the acquisition of a myofibroblast 
phenotype and contractile function163,164. 
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Moreover, in the expression profiling study, the GO term 'collagen fibril formation' and KEGG 'PI3K-Akt 
pathway' was constantly overrepresented when DDtis was compared to controls (DDfat and CTtis), 
suggesting increased ECM stiffness and activated PI3K-Akt as two specific features related to DDtis. 
Recent studies proposed that the PI3K-Akt pathway is a key regulator linking the ECM stiffness and 
AS changes165. Future experiments on possible effects of both ECM stiffness and the PI3K-AKT 
pathway on DD-specific AS are needed. 
Taken together, this study provides a first insight into altered AS and the possible physiological 
pathways involved in AS regulation in DD tissues.  
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4.4 Therapeutic potential  
The expression profiling study suggests an activation of the YAP/TAZ mechanotransduction pathway 
in DDfat and DDtis compared to CTtis, which is likely to contribute to the activation of adipo-
fibrogenesis and continuous induction of the TGFβ fibrosis pathway. YAP/TAZ pathway is considered 
as a reader of ECM stiffness. Recently Dupont et al. have proposed a promising strategy to inactivate 
YAP/TAZ activity by culturing cells on soft matrices, which limited YAP/TAZ activity in cells and 
reduced growth140. Therefore, targeting the YAP/TAZ pathway represents a promising mechano-
interference strategy to block the link between ECM stiffness and pro-fibro induction and prevent 
fibrosis progression. 
The AS analysis suggests a fibrosis-specific feature related to DD tissue. This immediately incites to 
explore the potential to target AS in DD tissues. Therapeutic strategies can be designed to target the 
DD specific isoforms (for example, the dominant CD44s isoform expressed in DDtis and DDfat), the 
splicing factor expression or to use antisense-mediated splicing modulation166.  
In addition, the distinct AS usage of COL3A1 and distinct expression profiling within DD samples 
supports the presence of DD subgroups (DD subgroup 1 and 2) in the DD cohort used for RNA-seq. 
Stratification of patients into more homogeneous subgroups, for example using COL3A1 AS pattern, 
are likely to improve therapeutic efficacy of certain pharmaceutical agents. For example, DD tissues in 
DD subgroup 1 exhibited enhanced COL3A1 AS usage. By GO term and pathway overrepresentation 
analysis on DEGs in DDtis from subgroup 1 compared to subgroup 2, increased ECM stiffness and 
overrepresented PI3-Akt signaling pathway were suggested. A recent study suggested that in the 
presence of cell contractility, the ECM stiffness could regulate AS via PI3K-AKT pathway165. If this 
mechanism proves to be true in DDtis, modulating PI3K-Akt activity using small molecules might 
represent an effective treatment of DD for DD subgroup 1 patients.   
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4.5 Concluding remarks and a model of DD development 
DD is a common complex disease with a major genetic component (~ 80%). Large pedigrees even 
suggest the existence of monogenic forms with an autosomal dominant mode of inheritance21. DD is 
typically observed in adults with a manifestation age of 55-6497. It is rarely seen in adolescents. The 
late-onset manifestation of DD suggests that the effects of genetic predispositions develop over 
time or interact with enviormental factors167. Consequently, it is difficult to ascertain the causal 
variants contributing to DD. Additionally, variant identification captures only one layer of the genomic 
features of DD. Thus there is a need to integrate genomic approaches to fully characterize the multi-
layered genomic features of the DD-associated traits. 
This study investigated the genetic architecture and molecular basis of DD at different levels 
including a GWAS locus, genome wide rare variants and candidate genes, gene expression and 
alternative splicing as well as pathways.  
First, as a follow-up of GWAS, targeted NGS of the most significant locus at 7p14.1 revealed two 
GWAS risk haplotype-related variants, a rare coding SNV and a common eQTL candidate, both 
in EPDR1. This suggests the observed association on the short arm of chromosome 7 may 
represent both rare and common variants in EPDR1, a verified functional candidate gene 
involved in ECM-receptor interactions, which contributes to the contractile phenotype of DD 
primary cells123. 
Second, by whole exome sequencing in combination with expression analysis, 6 functional 
candidate genes carrying rare variants were prioritized and they may represent genes underlying 
the genetic vunerability to develop DD.  
Third, by whole transcriptome analysis, the potential key mechanisms in DD pathogenesis were 
revealed, which included mechanotransdution pathways (in particular the Hippo signaling 
pathway) that provide a profibrotic microenvironment, followed by induction of major fibrogenic 
mediators (enhanced ECM-receptor interactions and alternative splicing) that induce fibroblasts to 
acquire a fibrotic phenotype and promote DD progression. In addition, common pathways were 
shared among different levels suggesting a genetic network involving interactions among the 
Hippo network (including the YAP/TAZ pathway, WNT/β-catenin pathway, TGFβ pathway), the 
PI3K-Akt pathway and ECM-receptor interactions.  
Taken together, here I proposed a preliminary model of DD development. The myofibroblasts in 
DDtis are potentially derived from the palmar fat tissue (DDfat). The adipocyte-fibroblast 
differentiation is first induced by the Hippo network to establish a profibrotic niche. The niche 
components further induce fibrotic factors (including enhanced ECM-receptor interactions and 
alternative splicing etc.) to mediate the fibroblast-myofibroblast transformation. The deregulated 
activity of myofibroblasts increases the ECM stiffness and and exert contractile forces on the 
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ECM. A mechano-feedback response between myofibroblasts and their stiff ECM is continuously 
mediated by increased ECM-receptor interactions, the YAP/TAZ pathway and PI3K-Akt pathway. 
Moreover, a genetic burden on the Hippo network or ECM genes can potentially increase the risk 
to develop DD. Overall, this study sheds light on likely mechanistic links between the genetic 
predisposition and the development of DD.  
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Figure 4-1 A preliminary model of DD development 
In the palmar adipose tissue, the Hippo network first activates the adipocyte-fibroblast differentiation to 
establish a profibrotic niche. Factors released by the niche further induce fibrotic mediators (enhanced 
ECM-receptor interactions and alternative splicing etc.), which lead to transformation of fibroblasts into 
myofibroblasts with prodigious fibrillar ECM accumulation and excessive cell contraction. A mechano-
feedback response between cells and their stiff ECM is mediated by enhanced ECM-receptor 
interactions, the YAP/TAZ pathway and PI3K-Akt pathway. A genetic predisposition in the Hippo network 
or ECM genes can increase the risk of developing DD.  
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